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ABSTRACT 
Chemotherapy-induced nausea and vomiting (CINV) occurs in 70-90% of those 
receiving moderate-to-high emetogenic chemotherapy (Mastrangelo, 2018; Ranganath 
et al., 2015). Early management of chemotherapy side effects improves patient 
outcomes and decreases hospitalizations. The purpose of this DNP project was to 
utilize an evidence-based strategy to minimize CINV and to reduce the number of health 
care visits related to CINV over a 16-week period. The Iowa Model provided the 
framework for this project. A literature search was conducted of five databases, which 
yielded nine relevant articles. Evidence levels include four level II, four level VI, and one 
level VII, according to Melnyk and Fineout-Overholt’s (2015) hierarchy of evidence. The 
JHNEBP Research Appraisal Tools were used to appraise the evidence: seven pieces 
of evidence were rated high quality and two pieces were rated good quality. For this 
project, treatment naïve patients receiving moderate or high emetogenic chemotherapy 
received telephone calls on Days 2, 3, and 10 post-chemotherapy. The Rhodes Index of 
Nausea, Vomiting, and Retching (INVR) questionnaire was administered during each 
call and additional interventions were recommended based on INVR scores. The 
findings show that a telephone intervention and administration of a nausea 
questionnaire, while not necessarily decreasing overall CINV scores, did address 
symptoms in a cost-effective manner. There was an increase in infusion center visits 
that attributed to a decrease in ED visits and hospitalizations. Six of the 45 comparison 
group patients required hospitalizations for CINV (13.33%), compared to 1 of the 24 
intervention group participants (4.17%).  
Keywords: CINV, INVR, telephone intervention 





Nausea and vomiting are the most common side effects of chemotherapy, occurring in 
70-90% of patients receiving moderate or high emetogenic chemotherapy (Mastrangelo, 2018; 
Ranganath et al., 2015). Although nausea or vomiting can occur independently in patients 
receiving chemotherapy, they often occur together and are labeled CINV. CINV can be 
classified into five types: acute, delayed, anticipatory, breakthrough, and refractory (Adel, 2017; 
Moradian & Howell, 2015). Acute CINV occurs within 24 hours of initial administration of 
chemotherapy; delayed CINV occurs after 24 hours but may peak in two to three days (Adel, 
2017). Patients who have previously experienced CINV may experience anticipatory CINV, 
which occurs when a sensory experience (e.g., smell, sound, or taste) triggers a response prior 
to administration of subsequent chemotherapy (Adel, 2017). Breakthrough CINV occurs within 
five days of chemotherapy despite the use of a guideline-recommended antiemetic agent, while 
refractory CINV consistently occurs in ongoing chemotherapy despite the use of guideline-
recommended antiemetic agents (Adel, 2017). 
There are different pathways in the body which induce emesis, each relying on a set of 
different neurotransmitters (e.g., serotonin, dopamine, histamine, and substance P). Receptors 
for these neurotransmitters are found in high numbers in the dorsal vagal complex, area 
postrema, and gastrointestinal (GI) tract (Hornby, 2001). Traditional chemotherapy agents e.g. 
cisplatinum [cisplatin] damage the GI tract and cause calcium dependent exocytic release of 5-
hydroxytryptamine (HT3) from enterochromaffin cells in the GI mucosa (Hornby, 2001). 
Released 5-HT3 binds to its receptors on the vagal afferent neurons and this binding activates 
the chemoreceptor trigger zone (CTZ) and vomiting center (VC) (Ranganath et al., 2015). Once 
activated, the VC modulates efferent transmission to respiratory, vasomotor and salivary 
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centers, as well as to abdominal muscles, the diaphragm and the esophagus, resulting in 
emesis (Ranganath et al., 2015). This occurs with moderate or high emetogenic chemotherapy, 
particularly cisplatin (Hesketh et al., 2017). 5-HT3 receptor antagonists, neurokinin 1 (NK1-) 
receptor antagonists and dopamine antagonists have proven to be effective in preventing CINV 
(Ranganath et al., 2015). 
In addition to the treatment-specific risk factors for developing CINV, patient-specific risk 
factors have also been identified. Although some variability in patient-specific risk factors relates 
to the chemotherapy regimen, the most frequently identified patient specific factors are age and 
gender, along with a previous history of motion sickness and/or pregnancy-related nausea and 
vomiting, and previous CINV (Adel, 2017). Patients who are younger than 50 years and/or 
female are at a higher risk for developing CINV (Adel, 2017). 
Annually, 650,000 oncology patients receive chemotherapy in an outpatient oncology 
clinic in the U.S. (Centers for Disease Control and Prevention [CDC], 2019). Of these, an 
estimated 585,000 will experience CINV. Nausea and vomiting affect patients physically, 
psychologically and emotionally, which affects overall health and wellbeing. CINV has 
considerable negative impacts on physical, cognitive, social, emotional, and role functioning 
(Moradian & Howell, 2015). Research has demonstrated that CINV incidence is greatest on 
days 3-5 after chemotherapy treatment (Mastrangelo, 2018). Without CINV control, patients are 
more likely to miss treatments, stop treatments all together, and/or have burdensome and 
expensive hospitalizations (Traeger et al., 2015) 
Early detection and management of side effects of chemotherapy are important to 
improve patient outcomes, as well as to decrease hospital admissions and morbidity. Previous 
research studies have examined the advanced practice nurse’s role in promoting CINV 
management (Moradian & Howell, 2015; van Dusseldorp et al., 2018). Within these studies, 
researchers have demonstrated the potential to identify CINV and reduce psychological distress 
(Moradian & Howell, 2015). However, these studies have not been able to quantify the response 
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to patient concerns in real-time and its impact on CINV management (Trager et al., 2015). Aims 
of this evidence-based practice project (EBP) are to (a) identify CINV early in chemotherapy 
treatment and (b) implement successful interventions to reduce the complications encountered 
by patients experiencing CINV.  
Data from the Literature Supporting Need for the Project 
Cancer affects millions of Americans annually, whether they are patients, family 
members, health care professionals, or others. While there is great information and research 
available in the U.S. about cancer and its treatments, there is less emphasis of treating the side 
effects of cancer therapies. Because cancer is such an enormous health problem, it is simply 
too large to have high-quality, thorough research studies on all its aspects. The adult population, 
and most commonly the age bracket of 65-74 years, accounts for the bulk of cancer cases in 
U.S. (American Cancer Society [ACS], 2020a).  
Nausea and vomiting are two well-known side effects of chemotherapy and radiation 
treatments. With cisplatin use, the percentage on average of patients experience CINV 
increases to approximately 90% (Mastrangelo, 2018).  
A review of the literature demonstrated that using validated tools to measure CINV 
improves compliance with antiemetic treatments and leads to overall decreases in CINV (Basch 
et al., 2016; Mooney et al., 2017; & Sun et al., 2020). A number of studies have evaluated the 
effectiveness of telephone-based interventions in the management of CINV and other cancer-
related symptoms (Hintistan et al., 2017; Jackson et al., 2019; Mooney et al., 2017; Rico et al., 
2017; & Sun et al., 2020). Electronic systems have been developed to help facilitate symptom 
monitoring and management (Traeger et al., 2015). The interventions have been designed to 
improve patient-provider communication, alert providers to significant symptom issues, and 
support provider decision-making (Sun et al., 2020). Mobile phone and computer-based 
systems have been used by outpatients receiving chemotherapy as a symptom monitoring and 
management method and alert system for the cancer care team (Beck et al., 2017). 
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National Data: Cancer Statistics 
 The incidence of cancer in the U.S. from 2011-2015 was 439.2 per 100,000 men and 
women, with cancer mortality of 163.5 per 100,000 (National Cancer Institute [NCI], 2018). Even 
with how far cancer treatment has come, these numbers still remain staggering and these 
abbreviated statistics reflect the burden of cancer on society. These impacts are economical, 
psychosocial, and of course, physical. These expenditures reached $147.3 billion in the U.S. in 
2017, and they are only increasing (NCI, 2018). This data focuses on adults with cancer and the 
most common cancers in the U.S., but there are many other alarming statistics.  
The above data focuses on adults with cancer and the most common cancers in the 
U.S., but there are many other alarming statistics. Males in the U.S. have a 40.14% lifetime risk 
of developing an invasive cancer and also have a 21.34% lifetime risk of dying from an invasive 
cancer (ACS, 2020a). For females, the lifetime risk of developing an invasive cancer is 38.70%, 
while the lifetime risk of dying from an invasive cancer is 18.33% (ACS, 2020a). Patients with 
invasive cancers are more likely to require intensive therapies that include emetogenic agents.  
State Data: Cancer Statistics  
 For Indiana, new cancer cases for 2020 totaled 37,940, with 13,630 deaths (ACS, 
2020a). From 2012-2016, the incidence of cancer for Indiana residents was 457.1 per 100,000 
men and women and the cancer mortality from 2013-2017 was 175.6 per 100,000 men and 
women (ACS, 2020a). While the data were not exactly equivalent to national data, they were 
generally similar. Within Indiana, lung cancer has the largest percentage of new cases in 2019 
(5,700), followed by breast (5,410), prostate (3,570), and colorectal (3,410) (ACS, 2020a). 
These statistics reflect the national population and further demonstrate the seriousness of the 
problem of cancer burden. Furthermore, considering the fact that Indiana residents with the 
most prevalent cancer (lung cancer) often receive moderately or highly emetogenic therapy, it 
could be projected that 5,130 newly diagnosed lung cancer patients experience CINV annually. 
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Local Data: Cancer Statistics  
Region X encompasses the majority of Madison County, Indiana (Health Network X, 
2018). This region has a slightly higher average age and percentage of older adults compared 
to other surrounding Indiana counties and has a lower median household income than Indiana, 
as well as the surrounding counties, with a poverty level at 19% (Health Network X, 2018). 
These economic statistics, combined with higher rates of unemployment and education levels, 
put this region (identified as a medically underserved area) at risk for poor health outcomes.  
Reflective of the socioeconomic impact on health, Region X had higher rates of breast, 
lung, oral cavity/pharynx and prostate cancers than Indiana and the U.S. (Health Network X, 
2018). The region was identified as in need for increased access for services related to lung 
cancer (Health Network X, 2018). As lung cancer therapies commonly include moderately 
emetogenic chemotherapy, it can be inferred that the region specifically needed CINV 
management resources, because the patient population had limited health care resources 
outside of the hospital and oncology office settings.  
Data from the Clinical Agency Supporting Need for the Project 
The Regional Cancer Center within Region X provided care for 60-70 oncology patients 
daily, five days a week, among three oncologists. The most common cancers seen in this 
patient population were lung cancer, head and neck cancers, colon cancer, and breast cancer 
(Oncologist Y, February 24, 2020). Colon and breast cancers commonly were treated with the 
standard of care identified by Ranganath et al. (2015), combinations of cisplatinum and 
doxorubicin, chemotherapeutic agents with high emetogenic potential. The most common 
reasons oncology patients had sought additional office appointments was nausea and vomiting, 
which has been noted to occur in up to 90% of the patients seen within this practice (Oncologist 
Y, February 24, 2020). Consistent with findings reported in the supportive literature (Gyawali et 
al., 2016), these admissions and additional, unscheduled office visits put strains on patients 
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financially, and providers in the Regional Cancer Center had been challenged by the additional 
time required to provide the best care to their patients.  
Of the 45 patients used for comparison data, one patient (out of 45) required a visit to 
the infusion center (2.22%). Twenty-three patients went to the ED. Several patients went to the 
ED more than once (56 total visits). Ten of the ED visits were related to CINV (22.22%). 
Seventeen patients had hospitalizations for the comparison group (37.78%). Four of these 
hospitalizations were related to CINV (8.89%). Several patients also had more than one 
hospitalization. 
Key stakeholders at the Regional Cancer Center identified their patient population as 
lacking in educational resources to self-manage CINV. The oncologists and their support staff 
noted that their patients have low knowledge bases about cancer and cancer treatment. For this 
reason, it was determined that an advanced practice provider (APP) would be optimally suited 
to bridge the gap in education; the Doctor of Nursing (DNP) practice student served in this role. 
Using an established nausea questionnaire and providing additional guidance and education via 
telephone was designed to reduce the impact of CINV that patients experience in one of the 
most stressful times of their lives.  
Purpose of the Evidence-Based Practice Project 
The reduction of CINV remains a major clinical issue, as CINV is directly related to 
adherence to scheduled chemotherapy treatments and maintenance of patient quality of life 
(Coolbrandt et al., 2018). The purposes of this EBP project were to limit CINV and to determine 
the impact of interventions on reducing the number of health care visits related to CINV.  
PICOT Question 
 Specifically, this project addressed the following PICOT question: In adult patients with 
cancer who are undergoing chemotherapy, does a telephone intervention which includes the 
administration of a nausea questionnaire and APP-guided interventions at Days 2, 3 and 10 
post-chemotherapy decrease infusion center visits, emergency department (ED) visits, and 
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hospitalizations related to CINV complications as compared to current practice (no telephone 
follow-up or nausea questionnaire) over a 16-week period of time? 
Significance of the EBP Project 
 This project was designed to have a significant impact on patients and health care 
professionals. Cancer treatment symptom management improves patient and family quality of 
life, leads to better treatment compliance and offers survival advantages (Jackson et al., 2019). 
It has become obvious, within the literature, that there are needs for improvements in care and 
the management of these cancer side effects (Moradian & Howell, 2015). With the accessibility 
and functions of advancing technology, interventions involving telephones remain a crucial 
component of health care. With integration of self-management strategies, a great need for an 
intermediary between patients, technology, and health care providers has developed. The DNP 
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CHAPTER 2 
EBP MODEL AND REVIEW OF LITERATURE 
Evidence-based Practice Model 
Overview of EBP Model 
The Iowa Model Revised: Evidence-Based Practice to Promote Excellence in Health 
Care was chosen because of its applicability to the clinical problem, and permission for use was 
obtained (see Appendix A). This model has multiple phases and feedback loops to promote 
change, which is appropriate for a clinical problem of this severity. The Iowa Model was 
developed for multidisciplinary care teams and has been revised and updated. It is composed of 
several stages.  
The Iowa Model begins by encouraging clinicians to identify triggering issues or 
opportunities (Iowa Model Collaborative, 2017). These can be from a variety of sources, 
including a patient or clinical issue, organizational, state, or national issue, from new evidence, 
from accrediting agency requirements, and/or based on the health care system’s philosophy of 
care (Iowa Model Collaborative, 2017). The next stage is to state the question or purpose; this is 
followed by forming a team (Iowa Model Collaborative, 2017). This is an important step in the 
overall process and provides a key EBP model component: the multidisciplinary team approach 
of the model.  
The next stage of the model is to assemble, appraise, and synthesize the body of 
evidence. This is done via systematic searching and leveling the evidence (Iowa Model 
Collaborative, 2017). Following a systematic search for and leveling of evidence, which is 
outlined in the remainder of this chapter, the next important stage is to design and pilot the 
practice change (Iowa Model Collaborative, 2017). The implementation plan is finalized, an 
evaluation plan is established, participants are engaged in the intervention (piloted practice 
change), and post-pilot data are collected (Iowa Model Collaborative, 2017).  
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Once pilot data has been reviewed, it is important for the team to consider if the practice 
change is appropriate to fully adopt into practice. If so, the organization has to integrate and 
sustain the practice change (Iowa Model Collaborative, 2017). They may also need to hardwire 
the practice change into the electronic medical records (EMR) system and reinforce the practice 
change as necessary (Iowa Model Collaborative, 2017). 
 One assumption of the Iowa Model is that there will be an effective team to implement 
the EBP, including opinion leaders and change champions. The Iowa Model requires a core 
group, which is a select group of practitioners with the mutual goal of disseminating information 
regarding a practice change and facilitating the change in practice by other staff members in 
their unit or peer group (Everett & Titler, 2006). The Iowa Model also assumes users will have 
the education, practice, specialty, and innovative views that will allow for the adoption of the 
practice change. Outreach and consultation by experts are another important component of the 
Iowa Model; this allows for education and feedback. (Everett & Titler, 2006). Organizational 
variables are assumptions of the Iowa Model; these include access to researchers, authority to 
change practice and support from peers, other disciplines, and administrators (Everett & Titler, 
2006). The Iowa Model assumes there will be the roles of staff nurse, advanced practice nurse, 
nurse manager, associate director for clinical services, and a chief nurse executive (Everett & 
Titler, 2006); there are expectations for each of these roles.  
Application of EBP Model to DNP Project 
The Iowa Model was determined to be valuable for the EBP project, as the model clearly 
outlines a process to go through to implement a practice change. The multidisciplinary approach 
and incorporated feedback loops help all members follow the process, and the model was 
specific enough to allow project leaders to be able to clearly follow the stages. Thus, the Iowa 
Model was deemed to be suitable for guiding implementation of a telephone intervention to 
address CINV in an oncology office setting.  
CINV REDUCTION                10 
 
 The first stage of the Iowa Model, identifying a triggering issue or opportunity, was 
undertaken earlier. The oncologist within the Regional Cancer Center welcomed the DNP 
student, recognizing the opportunity to have a clinical problem addressed through a scholarly 
project led by the DNP student. The oncologist had reported that barriers were impacting the 
quality of life for patients undergoing chemotherapy and a limitation of services was in conflict 
with the health care system’s philosophy of care. This led to the next stage of the Iowa Model, 
and a question or purpose was developed. Given that the practice values quality of life for 
patients undergoing chemotherapy yet has limited appointments and resources available to 
address CINV, what evidence-based interventions were viable to use. The next stage, stating 
the question or purpose, was completed by forming the clinically relevant PICOT question. This 
clinical question can be addressed through the EBP process and addresses an organizational 
priority for the Regional Cancer Center. Although those caring for the oncology patients at the 
Regional Cancer Center could already be labeled as a team, a specific team was formed for the 
purpose of the addressing this clinical issue, with the DNP student in a leadership role. Key 
stakeholders were identified and recruited. These individuals included the DNP student (serving 
in the leadership role of APP), the project facilitator/oncologist, the nurse manager, and clinical 
support staff.  
 Additional steps of the Iowa Model were followed as the DNP student searched for 
evidence regarding interventions for nausea and vomiting from chemotherapy. The evidence 
was made into a table of best sources. Within the next stage of the Iowa Model, the DNP 
student reviewed, critiqued, and synthesized the body of evidence so the team could work 
towards the next stage, designing and piloting the practice change. This step, DNP Project 
implementation and evaluation, was completed in a controlled environment with data 
measurement using the INVR questionnaire (see Appendix B) to create a care map for nausea 
and vomiting symptom management and evaluating the impact of this intervention on CINV-
related office visits. In addition to these stages of the Iowa Model, it was anticipated that the 
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DNP student would disseminate the findings of the pilot change to peers and others within the 
DNP program, the organizational system of the Regional Cancer Center, and local, regional, 
and/or national APRN professional organizations. Findings would then be published within a 
repository which serves as a central exchange for scholarship.  
 Following completion of piloting the practice change, led by the DNP student, it was 
anticipated that the remaining stages would be led by the oncologist and nurse manager, 
integrating and sustaining the practice change. If the telephone intervention with administration 
of a nausea questionnaire was successful, a plan for sustainability would be developed by the 
DNP student so that it could be adopted by the staff to use on all new oncology patients who 
would be seen in the office. Recommendations for redesign or revision would be provided. 
Depending on the success and applicability of the intervention, this could involve changes to 
medication regimens for CINV. It could also involve enlisting other health care disciplines to 
create a patient navigation program centering around CINV management. The plan for 
sustaining the practice change was anticipated to involve education and in-services for the staff, 
as well as education for the patients. It was also anticipated that the piloted change will be fully 
adopted by having protocols and order sets in the EMR that could be utilized by staff.  
Strengths and Limitations of EBP Model for DNP Project 
One strength of the Iowa Model for this DNP project was the model’s established 
success in leading practice change. The model has been widely used and its strengths have 
been established. A recent survey of 431 health care professionals revealed that 88% reported 
they had used the Iowa Model (Iowa Model Collaborative, 2017). The revised model was said to 
be a straightforward, linear format with necessary added detail on how to pilot practice change 
(Iowa Model Collaborative, 2017). Because of its revisions, the model now it contains fully 
developed materials, allowing for organized training, ease of adoption, and a user-friendly 
approach (Lloyd et al., 2016). The user-friendly design was integral to developing student 
understanding on how to use a systematic approach in making a significant practice difference 
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(as either a quality improvement project or new change process) (Lloyd et al., 2016). All of these 
identified strengths were essential to the DNP student leading this EBP change.  
Despite the number of strengths for using the Iowa Model for this DNP project, 
limitations also existed. One limitation of using the model for this DNP project was that it could 
be too complex for novice nurses (Iowa Model Collaborative, 2017). Other limitations included 
complexity of the arrows on the diagram of the model (which could make the model more 
difficult to follow); it would also be helpful if the model provided additional clarification on 
knowing when evidence is sufficient to change practice (Iowa Model Collaborative, 2017). In 
considering the stages of this DNP project, the DNP student was aware that she could be 
unable to complete the final stages of the project; sustaining practice change and disseminating 
results of the sustained project. The DNP student recognized these as limitations for this project 
but determined that the strengths and advantages outweighed the limitations. Thus, the model 
was deemed appropriate to guide this DNP project.  
Literature Search 
Sources Examined for Relevant Evidence 
The purposes of the literature search were (a) to find evidence to interventions for CINV 
and (b) to determine best practice interventions that reduce the incidence of CINV (see Figure 
2.1). 
Search Engines 
 The databases included were Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), The Cochrane Library, Joanna Briggs Institute (JBI), Medline (PubMed) and Nursing 
& Allied Health Database. 
Key Words 
 The key words used in the literature search were chemotherapy AND nausea and vomit* 
AND nurs*. 
Inclusion and Exclusion Criteria and Literature Search Results 
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 The limiters (inclusion criteria) used to obtain supportive evidence within all databases 
were the following: written in English, peer-reviewed, and published no earlier than 2015. Within 
the Nursing & Allied Health Database, “chemotherapy” and “nausea and vomit*” were limited to 
abstracts.  
Articles were then excluded if they focused only on specific medications to reduce CINV. 
Based on input from the EBP team, articles were also excluded from further consideration if 
they did not include the practice change found to be best fit for the practice setting: a telephone 
intervention. Additionally, articles were excluded if they did not include a clear evaluation of 
nausea and/or vomiting. 
  The search in The Cochrane Library yielded 73 results for inclusion. The abstracts and 
four full-length articles were read, and one was found to meet both the inclusion and exclusion 
criteria. The CINAHL search yielded 76 results: 14 abstracts and full-length texts were read, and 
two were found to meet the inclusion and exclusion criteria. The JBI search yielded 56 results. 
Twenty article abstracts were read, as well as three full-length articles, but none met both 
inclusion and exclusion criteria. Medline resulted in 226 results: 14 abstracts were read, as well 
as four full-length texts, and two of these pieces of literature met both the inclusion and 
exclusion criteria. Finally, Nursing & Allied Health Database yielded 153 results. Twenty 
abstracts were read, seven full-length texts were read, and two were included after meeting the 
criteria. Two final pieces of evidence were found to meet the inclusion and exclusion criteria 
after citation chasing. In total, nine pieces of evidence were identified for applicability (see 
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Figure 2.1 
Literature Search Results 
 
Levels of Evidence 
Within the systematic search, nine sources were found to support the evidence-based 
practice change; each of these pieces of evidence were then reviewed and their level of 
evidence was determined. Melnyk and Fineout-Overholt’s (2015) hierarchy of evidence also 
provided guidance for this determination. The rating system for the hierarchy of evidence ranks 
sources into seven levels. The higher a piece of evidence ranks in the hierarchy, the more likely 
the results accurately represent the evidence (Melnyk & Fineout-Overholt, 2015). This gives 
researchers more confidence that their interventions will have similar outcomes.  Level I reflects 
the highest level of evidence and includes systematic reviews or meta-analyses of all relevant 
RCTs. Level II evidence is obtained from well-designed RCTs (Melnyk & Fineout-Overholt, 
2015).  Level III evidence is evidence from well-designed RCTs without randomization (Melnyk 
& Fineout-Overholt, 2015). Level IV evidence is evidence from case-control and cohort studies 
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and qualitative studies (Melnyk & Fineout-Overholt, 2015). Level VI evidence is evidence from a 
single descriptive or qualitative study (Melnyk & Fineout-Overholt, 2015). Finally, level VII 
evidence is evidence from authority opinions and/or reports of expert committees (Melnyk & 
Fineout-Overholt, 2015).  
There were four pieces of level II evidence, which consisted of evidence from at least 
one well-designed RCT (Basch et al., 2016; Franca et al., 2015; Mooney et al., 2017; & Sun et 
al., 2020) There were five pieces of level VI evidence, which were evidence from a single 
descriptive or qualitative study (Hintistan et al., 2017; Jackson et al., 2019; Karimi et al., 2017; 
Rico et al., 2017; & Underhill et al., 2015). Because Melnyk and Fineout-Overholt (2015) do not 
provide specific guidance for leveling EBP projects, a decision was made to rank evidence 
published by Underhill et al. (2015) as level VI, rather than expert opinion (level VII). There was 
one piece of level VII evidence, which is evidence from authority opinions and/or reports of 
expert committees (Moretto et al., 2019). 
 Appraisal of Relevant Evidence 
Following obtaining permission for use (see Appendix C), The Johns Hopkins Research 
Evidence Appraisal Tool and the Johns Hopkins Non-Research Evidence Appraisal Tool were 
used to appraise the evidence. Specifically, the Non-Research Evidence Appraisal Tool was 
used in the appraisal of the EBP project identified within the CINAHL search, and the Research 
Evidence Appraisal Tool was used to assess the nine remaining sources of evidence found in 
the review of the literature. Appraisal scores were determined by the DNP student after 
appraisal checklists were finalized. 
 When using the Johns Hopkins tools, high quality indicates reliable and generalizable 
results. The study must have a sufficient sample size for the study design, an adequate control, 
and definitive conclusions; the researchers must also provide consistent recommendations 
based on a comprehensive literature review that includes thorough referencing to scientific 
evidence (Dearholt & Dang, 2017).  Sources that meet these qualifications are given a quality 
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rating of “A”. Good quality evidence has reasonably consistent results. Good quality studies also 
have a sufficient sample size for the study design, has some component of control, and fairly 
definitive conclusions. The researchers should also provide reasonably consistent 
recommendations based on a fairly comprehensive literature review that included some 
references to scientific data (Dearholt & Dang, 2017). Sources that meet these checks are given 
a quality rating of “B”. A low-quality rating is given if there is little evidence with inconsistent 
results; there is an insufficient sample size for the study design, and conclusions cannot be 
drawn (Dearholt & Dang, 2017). Sources meeting these appraisal guidelines are given a quality 
rating of “C”. None of the sources from the evidence review were “C” quality sources.   
 A summary of the evidence supporting this EBP project, including quality ratings, can be 
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Table 2.1  
Literature Search Results 
Database/Resource      Keywords/Phrases Limiters Results Selected 
CINAHL       chemotherapy AND 2015-2020, 76  2 
        nausea and vomit*  English,    
        AND nurs*   Scholarly 
       Peer  
       Reviewed 
 
JBI        chemotherapy AND 2015-current 56  0 
        nausea and vomit*   
        AND nurs* 
 
Medline/PubMed      chemotherapy AND 2015-2020, 226  2 
        nausea and vomit*  English, 
        AND nurs*   Scholarly 
       Peer 
       Reviewed 
 
Nursing & Allied Health   ab(chemotherapy)  2015-2020, 153  2 
Database       AND ab (nausea and English,  
        vomit*) AND nurs*  Scholarly 
       Peer 
       Reviewed 
 
Cochrane       chemotherapy AND 2015-2020 73  1 
        nausea and vomit*   
        AND nurs* 
 
Citation Chased       21  2 
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Level II Evidence  
 Basch et al. (2016). Basch and colleagues (2016) conducted a non-blinded RCT to 
evaluate the Symptom Tracking and Reporting (STAR) system for cancer symptom 
management. The 12-symptom list measured symptom severity on a 0 to 4 numeric rating scale 
(0 not present, 4 disabling), capturing the most relevant list of high symptom burdens for cancer 
patients: appetite loss, constipation, cough, diarrhea, dyspnea, dysuria, fatigue, hot flashes, 
nausea, pain, neuropathy, and vomiting. The primary outcome was a change in health-related 
quality of life (HQRL) at 6 months from baseline. A secondary outcome was the number of 
emergency room visits and number of hospitalizations at one year. The sample included 766 
adults, recruited from September 2007 to January 2011. Inclusion criteria included (a) planning 
to receive chemotherapy at Memorial Sloan Kettering Cancer Center and (b) being able to read 
English.  
 Within the Basch et al. (2016) study, before randomization, participants were assigned to 
groups based on level of prior computer and email use: computer-experienced (those with 
regular access to a computer and at least weekly email use) and computer-inexperienced group 
(those not meeting computer-experience criteria). Participants in each of these groups 
(computer-inexperienced, n = 227; and computer-experienced, n = 539), were then randomized 
into usual care and STAR intervention. The mean age of all participants was 63 years, and the 
groups did not differ in baseline characteristics of cancer type and baseline HQRL. The 
researchers did note that the computer-inexperienced participants were significantly older, more 
often men, more often black, and less educated than those who were computer-experienced. 
 Within both the computer-experienced and computer-inexperienced groups in the Basch 
et al. (2016) study, those participants to usual care received symptom monitoring at the 
discretion of providers; symptoms were discussed at each clinical encounter with the 
oncologists and patients were encouraged to initiate telephone contact between visits for any 
symptoms that concerned them. Participants in the STAR intervention group who were in the 
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computer-inexperienced group (n = 155) self-reported symptoms using STAR at clinic visits only 
via wireless touchscreen tablets or free-standing computer kiosks. “A report tracking 
participants’ symptoms was printed at each clinic visit for the nurse and oncologist” (Basch et 
al., 2020, p. 558). Those in the STAR intervention group who were computer-experienced (n = 
296) were provided remote access to STAR and received a weekly reminder via email 
encouraging them to self-report their symptoms. In addition, this group’s reports triggered email 
alerts to nurses when symptoms reports worsened by  2 points or reached an absolute grade 
of 3 or higher. The most common symptoms that triggered email alerts were fatigue, pain, 
anorexia, dyspnea, neuropathy, and nausea. The system informed participants that emails were 
not routinely monitored after business hours and participants were instructed to call the office. 
Nurses were then able to address the symptoms via advice provided on the telephone (in 
response to 77% of email alerts) which resulted in the initiation or change in supportive 
medication for 12% of the email alerts.  
 Basch et al. (2016) compared the usual care group to the intervention group within the 
computer-experienced and computer-inexperienced (STAR) arms for HQRL. The mean HQRL 
score from baseline to 6 months improved among more participants in the STAR groups 
compared to the usual care groups. (34% vs. 18%, p < .001), with no more participants in the 
STAR intervention groups experienced improvement in HQRL by a clinically meaningful score  
6 points compared with usual care (21% vs. 11%). Those participating in the intervention were 
also less likely to note that their symptoms worsened; the mean HQRL score from baseline to 6 
months worsened among fewer participants in the STAR groups compared to the usual care 
groups (38% vs. 53%, p < .001) and fewer experienced a worsening of 6 or more points (28% 
vs. 37%, p < .001). Mean HQRL scores declined by less in the STAR groups compared with 
usual care (M = 1.4 vs. M = 7.1, p < .001); these results achieved statistical significance in the 
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larger computer-experienced group (p = .006, p < .001) but were not statistically significant in 
the smaller computer-inexperienced computer group.  
 Additionally, fewer participants in the STAR group had visited the emergency room 
within one year as compared to the usual care group (34% vs. 41%, p = .02). Basch et al. 
(2016) reported that there were fewer participants hospitalized from the STAR group at one year 
than the usual care group (44% vs. 49%, p = .08). 
 Basch et al. (2016) concluded that the STAR web-based symptom reporting with 
automated clinical email alerts resulted in better HQRL, fewer ER visits, and fewer 
hospitalizations. The researchers concluded that self-reporting improves the experience, 
efficiency, and outcomes of oncology care as it related to chemotherapy symptom burden. 
 Using the Johns Hopkins Research Evidence Appraisal Tool, this piece of evidence was 
rated as “A” quality evidence. This research study supported that a telephone supplemented, 
nurse-guided intervention is appropriate and feasible for cancer symptom management, 
including CINV.  
Franca et al. (2015). Franca and colleagues (2019) conducted a non-blinded RCT to 
evaluate the effectiveness of telenursing to reduce CINV. The sample included 61 adults 
receiving moderate or highly emetogenic chemotherapy in Brazil, who were reported to be 
homogenous in regard to sociodemographic and clinical characteristics.  
Baseline measure of CINV was obtained and patients were randomized into control (3-
minute telephone calls to primarily evaluate CINV, but general guidance was also provided) and 
experimental group (10-minute telephone calls providing detailed CINV education and 
management strategies [mechanism and triggering factors; scientific knowledge; preventive 
dietary, environmental, and behavioral measures; pharmacological intervention; and 
psychological support] that were tailored for each telephone call). Telephone calls were made 
for both groups five to six hours after administration of chemotherapy, 24 hours after 
administration, three days after therapy, and five days after treatment.  
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CINV was evaluated using the MASCC Multinational Association of Supportive Care in 
Cancer (MASCC) and the MASCC Antiemesis Tool (MAT) cancer patients. The scale measured 
if nausea and/or vomiting had been experienced since the last chemotherapy (0 = yes and 1 = 
no). If one of those symptoms was present, patients graded the severity of symptoms with 
scores from 1 (mild) to 10 (severe). The mean scores at each of the post-chemotherapy 
telephone call time periods were compared using t-tests.  
Nausea occurrence and intensity increased 24 hours after chemotherapy and peak 3 
days after treatment for both groups. But the experimental group had a lower occurrence (t-
scores not reported) than the control group during each of the telephone calls, achieving 
statistical significance at 24 hours (M = .300 vs. M = 5.483, p = .05). Statistical significance was 
more apparent in the degree of nausea experienced between the groups at 24 hours (M = .933 
vs. M = 2.219, p = .0347), 3 days (M = 2.064 vs. M = 4.1, p = .0295), and 5 days (M = 1.3 vs.  
M = 3.29, p = .0069) after therapy. Occurrence of vomiting was limited in both groups, with the 
highest occurrence (M = .100 vs. M = .3878, p = .008) and number of episodes (M = .300 vs.  
M = 1.1935, p = .020) at 3 days after chemotherapy. 
Franca et al. (2015) concluded that the intervention was effective at a time when CINV is 
most prevalent and likely more difficult to control. The researchers stress the importance of 
organizational support and training for full implementation of this intervention. 
Using the Johns Hopkins Research Evidence Appraisal Tool, this international research 
article rated as “A” quality evidence. The effectiveness of the telephone intervention and guided 
educational component, which can be provided by an APRN, supports the intervention being 
developed this EBP project.  
Mooney et al. (2017). Mooney and colleagues (2017) conducted an RCT to test the 
efficacy of an automated symptom management system in reducing chemotherapy-related 
symptoms. The sample included 358 adult oncology patients beginning chemotherapy; 180 
were randomized to the symptom care at home intervention, while 178 received enhanced usual 
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care. Inclusion criteria included (a) age 18 years or older; (b) life expectancy of at least 3 
months; (c) beginning a cancer chemotherapy course planned for at least 3 cycles; (d) English 
speaking; and (e) having daily access to a telephone. The average age of participants was 55.8 
years, and they were mainly Caucasian and female. “There were no significant differences 
between the control and intervention groups for demographic or disease variables and symptom 
severity at baseline” (Mooney et al., 2017, p. 542).  
All participants in the Mooney et al. (2017) study (control and intervention) reported 
symptom data in a daily phone call within an automated system. The automated system 
gathered data on the presence of 11 symptoms (fatigue, difficulty sleeping, nausea and 
vomiting, pain, numbness and tingling, feelings of depression, feelings of anxiousness, distress 
over appearance, diarrhea, sore mouth, and difficulty thinking or concentrating); severity of 
symptoms was rated on a scale of 0 to 10: 0 (none); 1-3 (mild); 4-7 (moderate); and 8-10 
(severe). The intervention group then received automated self-care management messages and 
were further managed via telephone by NPs who used a guideline-based decision support 
system to address poorly controlled symptoms, while the enhanced usual care group were 
reminded by the system to call their provider for symptom concerns. Data were collected daily 
for six months, unless the patient’s chemotherapy course was completed earlier.  
During the study period, Mooney et al. (2017) found that the most commonly reported  
symptoms of a moderate or severe level for at least one day included fatigue (86% of 
participants), pain (80%), difficulty sleeping (78%), and nausea/vomiting (60%). Patients in the 
intervention group had 67% fewer symptom days (p < .001) and 39% less moderate days (p = 
.001) than the enhanced usual care group. Mean nausea and vomiting severity ratings were 
significantly less in the SHC group: t = 2.769 (p = .006). 
Mooney et al. (2017) concluded that their research provided strong evidence that the 
telephone-based intervention for symptom management was efficacious and significantly 
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reduced symptom burden. The researchers opined that this system could provide an extension 
of care and was particularly applicable for rural communities.  
Using the Johns Hopkins Research Evidence Appraisal Tool, this research article rated 
as “A” quality evidence. The effectiveness of the telephone intervention and NP-guided 
management for severe symptoms of CINV was especially pertinent to this EBP project.  
 Sun et al. (2020). Sun and colleagues (2020) conducted a non-blinded RCT to evaluate 
the effect and feasibility of the SMILE (Symptom Management Improves your LifE) system in 
cancer symptom management. The sample included 324 adults, recruited from December 2015 
to November 2017, who were adult breast, gastric, or lung cancer patients starting adjuvant or 
palliative chemotherapy treatment. The mean age of participants was 52 years, and the 
randomized group did not differ in demographic or disease characteristics.  
Within the Sun et al. (2020) study, participants were randomized into a control group (67 
participants), experimental group 1 (135 participants), and experimental group 2 (122 
participants). The control group monitored symptoms using the cancer symptom management 
system. Experimental group 1 used the cancer symptom management system and symptom 
reports were provided to health care providers. Experimental group 2 used the cancer symptom 
management system; symptom reports were provided to health care providers and education 
was provided. The SMILE system included a 20-symptom list with severity score ratings from 0 
(no symptoms at all) to 10 (most severe possible). 
Sun et al. (2020) noted that to evaluate the additional benefit of the evidence-based 
symptom management education on symptom severity, only the experimental groups were 
compared. Although the main article focused on the symptoms of fatigue and sleep disturbance, 
other components of the symptom list were included in a supplementary, downloadable table. 
The mean score for nausea and vomiting at baseline was as follows: experimental group 1, M = 
3.2; experimental group 2, M = 2.7. Measured at prior to the fifth chemotherapy treatment, the 
mean score for nausea and vomiting had risen to M = 9.26 for experimental group 1 and only 
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M = 6.33 for experimental group 2; although this difference was likely clinically significant, it did 
not reach statistical significance (p = .709). The authors did also report a decreasing prevalence 
of nausea and vomiting among participants; nausea and vomiting were experienced by 13% of 
participants after the first cycle of chemotherapy, and, after symptom severity ratings and 
subsequent patient education, was experienced by only 8.5% of participants. In regard to the 
evaluation of the system (rated on a scale of 1 to 5), patients in experimental group 2 reported 
that the symptom management education was easy to follow (M = 4.01) and helpful for 
symptom management (M = 4.02). 
Pertinent to this project, Sun et al. (2020) concluded that the SMILE system could 
improve multiple symptoms and improves communication between patients and providers.  
 Using the Johns Hopkins Research Evidence Appraisal Tool, this piece of evidence was 
rated as “A” quality. Although a significant portion of the reported outcomes focused on sleep 
quality and fatigue, this research study supported patient acceptance for symptom management 
education, a key component of this EPB project. In addition, although not statistically significant, 
patients receiving symptom management education reported lower nausea and vomiting scores 
than their counterparts.  
Level VI Evidence  
 Hintistan et al. (2017). Hintistan and colleagues (2017) conducted a quasi-experimental 
study to determine the effects of a nurse telephone intervention for lung cancer patients. The 
sample included 60 patients with lung cancer recruited from Ambulatory Chemotherapy Unit at 
the Research Hospital between February 2013 to December 2013. Inclusion criteria included: 
(a) having lung cancer; (b) being between the ages of 18 and 65 years; (c) speaking Turkish; (d) 
being literate; (e) receiving their first chemotherapy treatment; (f) being informed about their 
diagnosis; (g) having a performance status of 2 or lower according to The Eastern Cooperative 
Oncology Group (ECOG) Performance Status; (h) having no operation related to cancer; (i) 
having a telephone connection; (j) having no chronic diseases or physical handicap; (k) being 
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conscious and able to communicate; (l) being able to understand the items on the scale; and 
(m) volunteered for the research. The primary objective of the study was to determine the 
therapeutic effects of a nurse telephone follow-up for lung cancer patients.  
 The Hintistan et al. (2017) study occurred over a 4-month period. There were no 
significant differences between the control and experimental groups. There were 30 participants 
in the control group and 30 participants in the experimental group. The researchers used 
several questionnaires for the study. In addition to a demographic questionnaire, they used the 
Eastern Cooperative Oncology Group (ECOG) Performance Status tool. This tool assesses 
patients illness quality of life and using a Likert scale (0 = no complaints, able to sustain normal 
activities; 1 = having tumor symptoms but able to sustain normal life activities; 2 = irritating 
tumor symptoms but up approximately more than 50% of waking hours; 3 = severely sick, 
limited to bed more than 50% of waking hours; 4 = entirely disabled, completely limited to bed; 5 
= deceased). Additionally, the Edmonton Symptom Assessment Scale (ESAS) was used. This 
tool assesses nine symptoms common to cancer patients, including pain, fatigue, nausea, 
distress, anxiety, drowsiness, changes in appetite, well-being, and shortness of breath. This tool 
also uses a Likert-type scale (0 = no symptoms, 10 = very severe symptoms). In this study, the 
researchers added three additional symptoms: skin and nail changes, mouth sores, and hand 
numbness. Finally, the Functional Living Index-Cancer (FLIC) was utilized to further evaluate 
quality of life in these cancer patients. This tool evaluates “physical function”, “psychological 
function”, “general well-being related to cancer”, “social function”, and “gastrointestinal 
symptoms”, for a total of 22 items. The tool calculates quality of life using a 7-point Likert scale, 
and higher scores indicate higher level functioning.  
 The control group was provided with standard care by the Ambulatory Chemotherapy 
Unit and no telephone follow-up. These participants completed the ESAS and FLIC after their 
first, third, and sixth chemotherapy treatments. The intervention group received standard care 
by the Ambulatory Chemotherapy Unit and a nurse telephone follow-up within a week after each 
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of the six chemotherapy sessions. The nurses administered the ESAS and FLIC after the first, 
third, and sixth chemotherapy treatments.  
 Hintistan et al. (2017) compared mean scores on the ESAS after the first, third, and sixth 
chemotherapy treatments. Subscale mean scores were lower in the intervention group 
compared to the control group for all subscale categories after the sixth treatment. Specifically 
related to this EBP project, nausea was significantly lower for the intervention group as 
compared to controls. For nausea, M = 7.37 vs. M = 8.23, p = .01. For the FLIC, gastrointestinal 
symptoms were less in the intervention group compared to the control group after each 
telephone call, although results did not reach statistical significance after the sixth session:, after 
the first chemotherapy session, M = 8.70 vs. M = 11.07, (p = .00);, after the third chemotherapy 
session, M = 7.87 vs. M = 9.20, (p = .00);, after the sixth chemotherapy session, M = 5.93 vs.  
M = 6.10, (p = .84). 
 The researchers concluded that the ESAS subscale scores for the intervention group 
were significantly better than the control group due to nurse telephone follow-up. The 
researchers found that the telephone follow-up helped manage side effects of chemotherapy, 
particularly vomiting (and oral mucositis). Thus, Hintistan et al. (2017) determined that a 
telephone intervention was a quick, effective method to improve the psychological and 
communicative needs of oncology patients. 
 Using the Johns Hopkins Research Evidence Appraisal Tool, this article rated as “A” 
quality evidence. This nurse-led, telephone-based intervention is especially applicable to this 
EBP project.  
Jackson et al. (2019). Jackson and colleagues (2019) conducted a pilot study to 
determine the impact of implementing a CINV collaborative disease therapy management 
protocol. The sample included 45 participants recruited from October 2016 to January 2017 who 
were seen in an outpatient oncology clinic and had a referral from a qualified provider to help 
manage CINV. Inclusion criteria included being seen in a Medical University of South Carolina 
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Hollings Cancer Center outpatient oncology clinic. The primary objective was to determine the 
impact of a CINV protocol in an outpatient oncology clinic setting. A variety of cancer patients 
were included in the study, including head and neck, breast, colon/pancreatic, lung, acute 
lymphoblastic leukemia (ALL), prostate, and Non-Hodgkin lymphoma.  
During the Jackson et al. (2019) study, which occurred over a 9-month period, 29 
patients were referred for the management services which were provided by a pharmacist. 
Forty-six percent of these patients were receiving highly emetogenic chemotherapy, and 41% 
were receiving moderately emetogenic chemotherapy. Forty-five patients were referred for 
management of CINV. Participants used the MASCC (Multinational Association of Supportive 
Care in Cancer) questionnaire for symptom scores, which were rated using a 10-point scale (0 
no nausea or vomiting, 10 worst nausea or vomiting) and received clinical interventions based 
on these scores. The management services included the use of a collaborative drug therapy 
management (CDTM) protocol/treatment algorithm. Interventions included addition of new 
medications (37% of referred patients), patient education (34% of referred patients), 
discontinuation of medications (10% of referred patients), and changing of doses, frequencies, 
and/or duration of medications (8% of referred patients). Pharmacists followed up with 
participants via a telephone call or during their next scheduled oncology visit. MASCC scores 
from only five of the 45 referred patients were available for evaluation post-intervention, limiting 
inferential data analysis, yet all of the five patients’ scores showed improvements from baseline. 
Median acute nausea scores decreased from 8 at baseline to 0 after intervention, while median 
delayed nausea scores decreased from 10 at baseline to 0 after consultation. Median initial 
scores for acute vomiting scores were decreased from 4 at baseline to 0 after intervention. The 
authors concluded that the collaborative approach, using a management protocol which 
included telephone follow-up, was an effective strategy to address CINV.  
Using the Johns Hopkins Research Evidence Appraisal Tool, this research article rated 
as “A” quality evidence. While a portion of the intervention was conducted during scheduled 
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clinic visits, the telephone-based follow-up is pertinent to this EBP project. While pharmacists 
were utilized in this intervention, their role could easily be assumed by an APRN, making this 
applicable to the EBP project. 
 Rico et al. (2017). Rico and colleagues (2017) conducted a pilot study to research the 
acceptance and perception of cHEmotHErApp, a smartphone application for oncology patients. 
The sample consisted of 14 cancer patients at the Oncology Service of the HE/UFPel in Rio 
Grande do Sul in Brazil. Patients were eligible to participate if they were: (a) adults (ages 18-
70); (b) started the first outpatient chemotherapy treatment between August and November 
2016; (c) had their own cell phone; (d) were literate; and (e) read and spoke Portuguese. The 
average age of participants was 44 years, and a majority of participants were female (64%). The 
primary objective was to evaluate the acceptance and perception of patients of the receipt of 
SMS text messages, as well as to evaluate possible benefits reported by participants.  
 The intervention began with registering patients on the cHEmotHErApp. Dates and 
hours of every outpatient chemotherapy session were indicated so that the periodicity of text 
messaging could be configured. Patients first received a text message to their cell phone 
informing them that they would receive daily guidelines on their treatment through free text 
messages. Every day during the period of time that a patient was receiving chemotherapy 
treatment, they received a randomly selected text message. The same message was not 
repeated within a 45-day span. The content of the text messages included guidelines on water 
intake, hygiene care, food intake, physical activity, prevention and management of nausea, 
vomiting, diarrhea, intestinal constipation, loss of appetite, and altered taste, as well as 
emotional support and encouragement.  
 A questionnaire was developed to identify patient perceptions regarding 
cHEmotHErApp. These considered of “yes or no” questions, Likert scale questions, and open 
answer questions. These included: whether the patient read the messages daily (yes or no), 
whether they understood the message guidelines (yes or no), whether they had difficulty 
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implanting the interventions (yes or no), if the messages were helpful in their treatment (yes or 
no), the reason(s) the messages helped their treatment (open answer), if the messages were 
considered to have any benefit (yes or no), the benefit of the messages (open answer), and the 
level of satisfaction of the messages (very satisfied, satisfied, neither satisfied nor dissatisfied, 
dissatisfied, or very dissatisfied). 
 All participants answered that they understood the content of the messages. All 
participants considered the messages helpful in their treatment, and all answered “yes” when 
asked if the messages had any benefit. Thirteen participants reported being “very satisfied” with 
the messages, and the remaining participant reported being “satisfied”.  
Rico and colleagues (2017) concluded that cHEmotHErApp was a helpful tool in guiding 
patients through chemotherapy treatment. The researchers found the text messaging 
intervention to be well-accepted by participants and to be particularly helpful in side effect 
prevention management (which included nausea and vomiting).  
 Using the Johns Hopkins Research Evidence Appraisal Tool, this evidence is rated as 
“B” quality evidence. While Rico and colleagues did not directly analyze the data specific to 
CINV, the acceptance of cell phone technology and pre-developed messages to guide self-
management of chemotherapy side effects provides additional support for this EBP project.  
Underhill et al. (2015). Underhill and colleagues (2015) conducted a nurse-led EBP 
project to monitor and improve CINV. The participants were 30 patients in an ambulatory 
oncology practice. Inclusion criteria were adult patients (at least 18 years of age) with a cancer 
diagnosis who were scheduled to start cycle one of a new chemotherapy regimen. There were 
more female participants than males (24 to 7) and the average age of participants was 56. 
Eleven participants were receiving high emetogenic chemotherapy, while 15 participants were 
receiving moderate emetogenic chemotherapy. Patients had one of several cancer diagnoses, 
including breast, lung, pancreatic, and colorectal. Underhill et al. (2015) noted, “The primary 
objective was to evaluate the process of implementing a structured, nurse-led assessment and 
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telephone follow-up intervention. A secondary objective was to evaluate the occurrence of acute 
and delayed CINV, describe the frequency of anticipatory CINV, and describe frequency of 
changes in antiemetic prescription after nurse-led intervention” (p. 38).  
Within the intervention a clinic nurse completed a structured telephone follow-up call at 
24- and 72-hours post-chemotherapy treatment. The MAT (Multinational Association of 
Supportive Care in Cancer Antiemesis Tool) was used to collect data. Participants answered 
“yes” or “no” for symptom experiences, and then symptom severity was measured on a scale 
from 0 to 10 (0 no symptoms, 10 worst symptoms).  
Within the EBP project, Underhill et al. (2015) found that reports of nausea decreased 
from 24 at the 24-hour call to 11 at the 48-hour call. Reports of vomiting decreased from three at 
the 24-hour call to two at the 48-hour call.  
The project leaders concluded that the intervention was feasible for outpatient oncology 
practices and was useful for patient symptom reporting. Symptoms that required intervention 
were easily identified by intervention nurses and appropriate follow-up was conducted.  
Using the Johns Hopkins Non-Research Evidence Appraisal Tool, this evidence is rated 
as “B” quality evidence. This telephone-based and nurse-led EBP project is applicable to the 
current EBP project.  
Level VII Evidence 
Moretto et al. (2019). Moretto and colleagues (2019) conducted an integrative review to 
identify the evidence for telephone follow-up by nurses for oncological patients undergoing 
chemotherapy in an outpatient clinic. They reviewed studies from the following databases: 
Literatura-Americana e do Caribe em Ciencias da Saude (LILACS), Banco de Dados em 
Enfermagem (BDENF), Medline, CINAHL, and Scopus. The keywords included were “Drug 
Therapy”, “Antineoplastic protocols”, and “Telephone”. Limiters were the past five years, and 
written in English, Spanish, or Portuguese. The searches for studies were conducted from 
September through October 2018. Inclusion criteria included: (a) original studies, (b) theme of 
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nursing intervention through telephone follow-up, and (c) treatment with outpatient 
antineoplastic chemotherapy. Exclusion criteria included (a) oral or intraperitoneal 
chemotherapy and (b) pediatric patients. The search resulted in 19 studies selected for review.  
Moretto et al. (2019) followed six steps for the integrative review process: (1) selection of 
the guiding question; (2) definition of the characteristic of the primary surveys of the sample; (3) 
selection of surveys that composed the review sample; (4) analysis of the findings of the articles 
reviewed; (5) interpretation of results; and (6) review report, providing a critical examination of 
the findings. Moretto et al. (2019) reported that the studies were evaluated using the Rating 
System for the Hierarchy of Evidence for Intervention/Treatment Question.  
The studies reviewed by Moretto et al. (2019) included a number of different designs: 
RCTs, quasi-experimental studies, observational studies, descriptive studies, and qualitative 
studies. The majority of the 19 studies were conducted in the U.S. and included patients with a 
variety of cancer types. Most of the telephone interventions occurred during the first week after 
chemotherapy treatment. In 13 of the studies, nurses led the telephone interventions (68.42%). 
There were a variety of results sought, including symptom control, specific symptom control of 
nausea and vomiting, fatigue, neurotoxicity, or a set of symptoms, HQRL, self-efficacy capacity, 
emotional support, and caregiver stress. Patient satisfaction with the intervention was 
addressed in eight studies. The synthesis of the evidence resulted in several themes, including 
management of chemotherapy-related symptoms, HQRL, self-efficacy, emotional support, 
caregiver stress, and patient satisfaction.  
Moretto and colleagues (2019) found significant support for the use of telephone-based 
interventions to address the health care for oncology patients. The researchers found nurse-led 
interventions to be an effective, innovative solution for patients receiving outpatient 
chemotherapy. 
CINV REDUCTION                32 
 
Using the Johns Hopkins Evidence Research Appraisal Tool, this evidence was rated as 
“A” quality evidence. The support for the use of telephone-based, nurse-led interventions for 
chemotherapy symptom management, including CINV, is applicable to this EBP project.  
Construction of Evidence-based Practice 
Synthesis of Critically Appraised Literature 
 Several detailed themes emerged from the review of the literature for implementation of 
an intervention aimed at reducing CINV (Basch et al., 2016; Franca et al., 2015; Hintistan et al., 
2017; Jackson et al., 2019; Karimi et al., 2017; Mooney et al., 2017; Rico et al., 2017; Sun et al., 
2020; & Underhill et al., 2015). One theme was that intervention involving technology and 
nurses/NPs for CINV management were accepted and feasible. While measured in various 
ways in the different studies, all mentioned that participants were satisfied with the format of the 
intervention and found it worthwhile and easy to use. Another theme that emerged was that this 
type of telephone intervention needs to become standard practice. It should be incorporated into 
EMRs and can serve as an extension of services (Mooney et al., 2017; Rico et al., 2017, Sun et 
al., 2020). Multiple researchers (Jackson et al., 2019; Mooney et al., 2017; Sun et al., 2020) 
mentioned that this type of intervention would be particularly helpful for rural populations or 
patients that live farther from where they receive oncology care.  
 Another theme that emerged was the idea of how best to implement this type of 
intervention. Some authors suggested it would be better to start this type of intervention later in 
the course of chemotherapy. Others suggested it would only be necessary for patients to 
participate in a phone intervention when symptomatic (Jackson et al., 2019; Karimi et al., 2017). 
Overall, the research supported the premise that a telephone intervention for CINV reduces 
symptom burden and improves patient’s health care related quality of life. Patients who 
experience less CINV require less office visits and hospitalizations related to chemotherapy side 
effects.  
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 One of the limitations that came out of the literature was that several of the analyses 
were retrospective in nature. Some researchers mentioned a lack of diversity in their study 
populations (Basch et al., 2016; Jackson et al., 2019; Mooney et al., 2017) and others were 
conducted in a single center or oncology practice (Karimi et al., 2017; Rico et al., 2017; Sun et 
al., 2020; Underhill et al., 2015). In addition, socio-economic factors, as well as environmental 
factors, as they relate to chemotherapy symptom management can be limitations. The social 
support and caregiver presence, or lack thereof, for chemotherapy patients can impact 
management greatly. This can be a difficult population to track long-term, unfortunately, and that 
was considered as a limitation in some studies.  
Best Practice Model Recommendation 
 The best practice recommendation, from the appraised-literature, was that all patients 
initiating chemotherapy should be educated about CINV, screened for CINV symptoms and 
warranted additional therapy, and provided guidance on the management of gastrointestinal 
side effects (including initiatives to prevent or minimize CINV). The use of a telephone 
intervention was strongly recommended within the literature.  
 Founded on the evidence from the review of the literature, the DNP student has chosen 
to implement an intervention aimed at reducing CINV. The EBP project was designed for the 
DNP student to follow a specific sequence for implementation of a CINV reduction program. 
Consistent with the reviewed literature, the intervention featured multiple telephone follow-up 
calls post-chemotherapy (which included the administration of a nausea questionnaire and 
recommendations for additional measures for CINV reduction, when warranted). Reflective of 
the supportive evidence, the patient-specific INVR questionnaire used within the Rhodes and 
McDaniel (1999) study was incorporated within this EBP project.  
How the Best Practice Model Will Answer the Clinical Question 
 This intervention was designed to answer the clinical question: Do follow-up telephone 
calls and discussion of CINV symptoms reduce symptom burden? Upon completion of the 
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literature review, the DNP student believed this intervention would reduce CINV symptom 
burden. Specifically, it was anticipated that participants who received telephone calls post-
chemotherapy would have less nausea and vomiting related to chemotherapy and better health 
care quality of life. Thus, the best practice model will answer the PICOT question: In adult 
patients with cancer who are undergoing chemotherapy, does a telephone intervention which 
includes the administration of a nausea questionnaire and APP-guided interventions at days 2, 
3, and 10 post-chemotherapy decrease infusion center visits, ED visits, and hospitalizations 
related to CINV complications as compared to current practice (no telephone follow-up or 
nausea questionnaire) over a 16-week period of time?    
  






















(usual care). 12 
symptoms were 
assessed weekly 
using a tablet or 
computer. 
Mean HQRL score from baseline 
to 6 months improved among 
intervention groups as compared 
to usual care (34% vs. 18%, p < 
.001), and more participants in 
the intervention groups 
experienced clinically meaningful 
HQRL improvement scores (21% 
vs. 11%).  
 
Mean HQRL score worsened 
among fewer in intervention 
group as compared to usual care 
(38% vs. 53%; p < .001), while 
participants in intervention group 
experienced a 6-point worsening 
in HQRL scores (28% vs. 37%; p 
< .001). 
 
Fewer intervention participants 
ED within 1 year (34% vs. 41%; p 
= .02). 
 
Fewer intervention participants 
were hospitalized at.1 year (44% 
vs. 49%; p = .08). 
 
STAR resulted in better HQRL, 
fewer ED visits, and fewer 
hospitalizations. 
II/A 
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RCT 61 adult 
oncology 
patients 
The control group 
received 3-minute 
telephone calls to 
evaluate CINV, as 













days after therapy, 
and 5 days after 
therapy. CINV was 
evaluated using the 
MASCC tool and 
MAT.  
The experimental group had 
lower occurrences of nausea 
compared to the control group 
during each of the telephone 
calls, with a statistically 
significant difference at 24 hours 
(M = .300 vs. M = .5483; p = .05). 
 
The degree of nausea 
experienced at 3 days was less in 
the experimental group (M = 
2.064 vs. M = 4.1; p = .0295). 
 
The degree of nausea 
experienced at 5 days was also 
less in the experimental group (M 
= 1.3 vs. M = 3.29; p = .0069). 
 
The intervention was effective at 
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Quasi-experimental 60 adult 
oncology 
patients 
The control group 
received standard 
oncology care. The 
experimental group 
received telephone 
follow-up by nurses 
after their first, 






with ESAS, FLIC, 
and ECOG.  
Subscale mean scores were 
lower in experimental group for 
all subscale categories after the 
sixth chemotherapy treatment per 
ESAS.  
 
Nausea was significantly lower in 
control group (M = 7.37 vs. M = 
8.23; p .01). 
 
GI symptoms were less in 
intervention group after each 
telephone call per FLIC scores.  
 
After 1st chemo session, GI 
symptoms were significantly 
lower in control group (M = 8.70 
vs. M 11.07; p = .00).  
 
After 3rd chemo session, GI 
symptoms were significantly 
lower in control group (M 7.87 vs. 
M 9.20; p = .00).  
 
After 6th chemotherapy session, 
GI symptoms were significantly 
lower in control group (M = 5.93 
vs. M = .6.10; p = .84). 
 
A telephone nurse-led 
intervention is successful in 
reducing symptoms of 
chemotherapy and improving 
HQRL. 
VI/A 
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Pilot study  45 adult 
oncology 
patients 
Patients received a 
referral from a 
qualified provider 
(pharmacist) to 








The MASCC tool 




MASCC scores for 5 patients all 
showed improvement from 
baseline after intervention(s). 
 
Median acute vomiting scores 
stayed at 0. 
 
Median acute nausea scores 
went from 8 to 0. 
 
Median delayed vomiting scores 
went from 4 to 0. 
 
Median delayed nausea scores 
went from 10 to 0. 
 
Pharmacists provided a 
substantial number of 
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randomized into the 




AMS daily reporting 




care messages and 
were further 






reminded by the 













Patients in the intervention group 
had 67% fewer symptom days (p 
 .001). 
 
Patients in the intervention group 
had 39% less moderate days (p = 
.001) compared to the enhanced 
care group. 
 
Mean nausea and vomiting 
severity ratings were significantly 
less in the SHC group: t = 2.769; 
(p < .006). 
 
Telephone-based intervention is 
efficacious and significantly 
reduces symptom burden.  
II/A 
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IR 19 studies 
included 


































Several themes emerged: 
management of chemotherapy-
related symptoms, HQRL, self-
efficacy, emotional support, 
caregiver stress, and patient 
satisfaction.  
 
Telehealth is an important 
component of multidisciplinary 
health care for oncology patients.  
 
Nurse-led interventions are 
effective for patients receiving 
outpatient chemotherapy.  
VII/A 
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Reference Design Sample Methods Major Findings & 
Recommendations 
Level/Quality 
Rico et al., 
2017 




was developed to 
deliver SMS text 
messages. The first 
text message was 
sent as initial 
















constipation, loss of 
appetite, and 
altered taste, as 




Evaluated with “yes or no” 
responses, Likert scale 
questions, and open answer 
questions: Whether the patient 
read messages daily (yes or no), 
whether they understood  
message guidelines (yes or no), 
whether they had difficulty 
implementing interventions (yes 
or no), if messages were helpful 
in their treatment (yes or no), 
reason(s) the messages helped 
their treatment (open answer), if  
messages were considered to 
have any benefit (yes or no),  
benefit(s) of the messages (open 
answer), and level of satisfaction 
of messages (very satisfied, 
satisfied, neither satisfied nor 
dissatisfied, or very dissatisfied). 
 
13 participants were “very 
satisfied” with the messages, and 
1 participant was “satisfied” with 
the messages. 
 
cHEmotHErApp is a helpful tool 
in guiding patients through 
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Reference Design Sample Methods Major Findings & 
Recommendations 
Level/Quality 
Sun et al., 
2020 





















addressed; use of 
SMILE also 
evaluated.  
CINV increased less with 
symptom management 
education. Experimental 1 group: 
M = 3.2 at baseline vs. 9.26 at 5th 
treatment; Experimental 2 group 
M = 2.7 at baseline vs. 6.33 at 5th 
treatment (p = .709). 
 
Experimental 2 participants 
reported the education was easy 
to follow (M = 4.01) and helpful 
for symptom management (M = 
4.02).  
 
Researchers noted that 
incorporating the system into 





EBP project 30 adult 
oncology 
patients 




call to the 




MASCC tool was 
used.  
Nausea decreased from being 
present in 24 patients 24-hours 
post-therapy to 11 patients 48-
hours post-therapy. 
 
Vomiting decreased from 3 
patients at 24-hours post-therapy 
to 2 patients at 48-hours post-
therapy. 
 
This intervention is feasible for 
outpatient oncology practices and 
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CHAPTER 3 
IMPLEMENTATION OF PRACTICE CHANGE  
Successful implementation of the evidence-based CINV management program 
could only occur after a rigorous review of the literature had been completed. The Iowa 
Model of Evidence-Based Practice was used as a guideline for implementation. 
Identification of the problem was clearly highlighted by the ACS, NCI, and CDC. The 
problem was emphasized as an important primary prevention health care concern for the 
patient population at Regional X Cancer Center in a Midwest town.  
The implementation phase involved planning the details of the specific intervention. 
It was a requirement to protect project participants and assess the practice setting where 
the intervention took place. After completing the university’s research determination 
questionnaire, it was determined that the project did not meet the federal government’s 
definition of human subjects’ research and no further oversight was required of the 
university’s institutional review board (IRB). Even with this determination, an IRB 
application was required at the parent hospital of the clinical site. The hospital’s IRB 
committee reviewed this EBP project to ensure the ethical treatment of all participants was 
maintained. Following permission to commence this EBP project (see Appendix D), the 
DNP student supervised its implementation.  
Participants safety and confidentiality were maintained using informed consent and 
education to all participants. The planning was detailed to share with the facility staff and 
participants. Data were collected, including information about past visits to the Regional 
Cancer Center and the ED. Survey data were also collected, which consisted mainly of 
participants demographic data. After the intervention, outcomes were revealed, and an 
analysis of the findings was completed. Extensive examination of the evidence surrounding 
this intervention was conducted.  
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Participants and Setting 
 The participants engaged in the practice change were adult oncology patients at 
Regional X Cancer Center. The average age of patients seen in this oncology practice for 
the group sampled was 67 years, with 57% male patients and 43% female patients. 
Participants were enrolled beginning August 3, 2020. Inclusion criteria were as follows: 
newly diagnosed adults (at least 18 years of age) oncology patients who were naïve to 
treatment and receiving high or moderate emetogenic intravenous chemotherapy. 
Exclusion criteria were pregnant or lactating females and participants who, in the opinion of 
project facilitator/physician, warranted individualized attention provided by the office staff.  
The project facilitator (Dr. X) was an oncologist with six years’ experience in 
oncology services. Another key stakeholder (Dr. Y), also an oncologist, had ten years’ 
experience in oncology services. The remaining staffing consisted of four registered 
nurses, five medical assistants, one practice manager, and two patient access staff 
members. The Regional X Cancer Center traditionally had seen 60-70 oncology patients 
daily among three oncology providers, five days a week. The practice had six patient rooms 
for initial and follow-up oncology visits among the three providers, as well as an infusion 
center on the second floor of the building. The infusion center staffed three registered 
nurses daily and one charge nurse and operated from 8:00a.m. to 5:00p.m. five days a 
week. This floor has served an average of eight patients for oncology and other (e.g. 
rheumatology) infusion services at one time. Participants were seen in the Regional Cancer 
Center oncology offices by Dr. X and Dr. Y. The project was approved by the medical 
director and practice manager. The participation of staff members was not expected, but 
staff was utilized for assistance with data measurements. The project facilitator aided in 
recruitment of participants. The identities of all participating patients remained anonymous. 
EMRs were reviewed for data collection purposes only.  
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Comparison Group Characteristics 
 Although basic demographic data for the historical patient population was provided 
by the office, a chart audit was conducted to gather data for statistical comparison. During 
the period prior to implementation, from March 1, 2020 to July 1, 2020, there were 45 new 
oncology patients treated at Regional X Cancer Center and receiving moderate and highly 
emetogenic chemotherapy. The average age of patients was 62.9 years. There were 
slightly more male patients (52%) compared to female patients (48%). There were a variety 
of cancer types, including lung, cervical, colorectal, breast, pancreatic, lymphomas, and 
others. A majority of patients were Caucasian (74%). 24% were African American, 1% was 
Hispanic, and 1% was of another race. Of the 45 new oncology patients, one required a 
visit to the infusion center. Additionally, 23 of the patients required visits to the ED. Patients 
often went to the ED multiple times, for a total of 56 ED visits. Of the 56 ED visits, 10 were 
directly related to CINV. Finally, 17 patients required hospitalization. Several of these also 
had multiple hospitalizations, for a total of 26 hospitalizations. Of these 26 hospitalizations, 
six were directly related to CINV.  
Intervention 
During the implementation period, from August 3, 2020, to January 2, 2021, 
potential participants were identified by the project facilitator (Dr. X) and referred to the 
DNP student. The first stage of the EBP project intervention was a screening visit for 
potentially eligible participants. This was done by obtaining information about the cancer 
diagnosis, cancer stage, and chemotherapy regimen from the EMR. The next step was 
conducted by the DNP student at the first appointment for a patient with a new cancer 
diagnosis that would require chemotherapy for treatment, consisted of obtaining informed 
consent, reviewing medical records, assessing vital signs, administering the demographic 
questionnaire (see Appendix E), and reviewing concurrent medications that may impact the 
plan of care. Those meeting inclusion criteria were approached by the DNP student, 
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advised about the change in procedure, provided detailed information about the 
intervention, and asked to participate. Those consenting to participate then completed a 
demographic questionnaire that asked questions about age, gender, race, marital status, 
educational level, employment level, and type of cancer. This questionnaire contained a 
medical record number (which was only available to authorized office staff who had access 
to the password protected computer system) that would allow for analyzing the 
effectiveness of the variable by demographic variable and was provided to the DNP student 
who placed each form (the consent and demographic forms) in a locked box in the project 
facilitator’s/oncologist’s office immediately following completion. The DNP student 
confirmed a phone number for contacting the patient and identified the most appropriate 
time for a call. The phone number, as well as designated date and time for the initial call, 
were added to the top right-hand corner of the Rhodes Index of Nausea, Vomiting, and 
Retching (INVR) form. The form included three copies of the INVR to assess symptoms on 
treatment Days 2, 3, and 10 and allow for prompt comparison of the severity of symptoms. 
These were kept secured at the home of the DNP student.  
The INVR questionnaire came from a direct source (Rhodes & McDaniel, 1999) 
(see Appendix B). The nausea questionnaire (INVR) includes eight Likert-type questions, 
scored from 0 (lowest) to 4 (highest), for a maximum score of 32. Patients select the 
answers that most closely correspond with their nausea, vomiting, and retching in the last 
24 hours.  
With day 1 being the first chemotherapy infusion, the telephone calls took place on 
Days 2, 3, and 10 of the chemotherapy cycle. On Day 2, the DNP student called each 
participant within 30 minutes of the preferred time, re-introducing herself and making an 
inquiry regarding the patients’ general well-being. Then, the INVR was administered and 
patients rated their CINV. The patient’s ratings were recorded on the coordinating INVR 
form by the DNP student. The form was kept in a locked box in a secure location in the 
DNP student’s home. Nausea and vomiting data obtained during the Day 2 ca ll served as 
CINV REDUCTION                43 
 
the baseline for future comparison. The Day 2 data questionnaire was designated to serve 
as the baseline data because, as the project facilitator/oncologist had noted, the onset of 
nausea and vomiting was typically not noted until Day 3. Prior to ending the call, the DNP 
student confirmed the ideal time for the next follow-up contact.  
During each of the calls, the DNP student initially reinforced the education provided 
regarding medications and other supportive measures to prevent and/or lessen CINV and 
then provided self-management interventions for CINV, developed by Dr. X and based on 
the scores of the INVR. Those with scores of 1 to 10 were advised to take their antiemetic 
medication as needed and drink a lot of oral fluids. Additional teaching for those with 
scores of 11-20 included taking their antiemetic medications on a regular schedule three 
times a day and to monitor oral fluid intake, with a goal of drinking at least 64 ounces of 
liquid each day. They were also advised that they would receive a telephone call from a 
nurse at the Regional X Cancer Center to further evaluate their symptoms within the next 
24 hours. Those with scores of 21-32 were advised that they would receive a telephone call 
from a nurse at the Regional X Cancer Center within the hour with further instructions.  
The Days 3 and 10 telephone calls followed the exact same format: initial data on 
nausea and vomiting was gathered using the INVR questionnaire, and self-management 
guidance was provided based on the overall score intensity on individual items, and 
presence of additional symptoms. The ideal time for follow-up contact on Day 10 was 
established at the end of the Day 3 call. 
At the end of the intervention, the DNP student reviewed the data. INVR scores 
were compared pre- and post-intervention; Day 2 to Days 3 and 10. Patient safety issues 
related to a CINV intervention were evaluated throughout the intervention.  
Validity and Reliability of Data Measures 
The Rhodes INVR has been used since the 1990s to evaluate nausea and vomiting 
associated with a number of medical conditions. Noting that reliable and valid self-reporting 
instruments were essential for managing nausea and vomiting, Rhodes and McDaniel 
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(1999) worked to revise the tool, while ensuring that it remained reliable and user-friendly. 
The reliability and validity of the self-report tool had been established through the previous 
research (Ahmad, 2005; Kim et al., 2007). Ahmad (2005) found that the tool had both 
validity and reliability with a Spearman Correlation Coefficient of .87, split-half reliability of 
.90, and Cronbach’s Alpha of .98. Additional international research (Kim et al., 2007) 
confirmed the tool’s validity and reliability, reporting Cronbach’s Alpha scores ranging from 
.912 to .968 and strongly correlated test-retest scores of all items (Spearman’s coefficients: 
.962-1.000, p < .0001).  
Comparison 
 To determine the intervention’s impact on self-reported CINV, patients INVR scores 
were compared at baseline (therapy Day 2) to therapy Days 3 and 10. To answer the 
PICOT question, the number of patients undergoing chemotherapy from August 3, 2020 to 
January 2, 2021 will be compared to patients receiving chemotherapy from March 1, 2020 
to July 1, 2020 in regard to infusion center visits, ED visits, and hospitalizations.  
Outcomes 
 The primary outcome of this EBP project was the need for additional health care 
visits related to CINV complications: infusion center visits, ED visits, and hospitalizations 
related to CINV. The number of visits for CINV complications was gathered from EMR 
records and compared to the comparison group data. 
 Secondary outcomes included a reduction in INVR scores from baseline (measured 
at Day 2) to follow-up telephone calls (measured on Days 3 and 10). For data analysis, 
patients’ scores were categorized into mild (INVR scores of 0-10), moderate (INVR scores 
of 11-20), and severe (INVR scores from 21-30) categories.  
Measures 
 The secondary outcome data were compared using the ANOVA statistic in the 
Statistical Package for the Social Sciences (SPSS). The Day 2 scores on the INVR 
questionnaire were compared to the Days 3 and 10 scores on the INVR questionnaire.  
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All data was entered into SPSS Statistics 25. Descriptive statistics (i.e. means, 
ranges, and percentages) were used to identify the group of participants by key 
demographic characteristics. A power analysis statistical test was run to determine the 
minimum number of participants and determined to be 51 participants in order to achieve 
statistical significance. An ANOVA test was run to compare mean scores of all participants 
from Day 2 to Days 3 and 10. Inferential statistics were used to compare participants who 
needed additional interventions (infusion center visits, ED visits, hospitalizations). One-way 
ANOVA testing and independent samples t-tests were used to compare scores between 
men and women. Paired samples t-tests also compared Day 2 scores to Day 3 scores, Day 
2 scores to Day 10 scores, and Day 3 scores to Day 10 scores. The primary outcome was 
to decrease symptom burden related to CINV via the INVR questionnaire and subsequent 
interventions. One secondary outcome was to document which interventions were required 
based on INVR questionnaire responses. Another secondary outcome was to determine 
which intervention regimens are utilized most often.  
Time 
 The EBP project intervention began August 3, 2020. Enrollment in the EBP project 
intervention was designed to last for four months, to coincide with the traditional influx of 
new patients at this Regional Cancer Center in the fall. This extended to five months, after 
recruitment was slower than planned. The project duration also helped ensure enough 
participants can be recruited (a minimum of 51 participants by power analysis) to maximize 
the probability of obtaining statistically significant results.  
Protection of Human Subjects 
 Prior to data collection, IRB approval was obtained by the DNP student. The DNP 
student and project facilitator completed the EBP project in accordance with protocol set 
forth by the IRB at Hospital X, obtained informed consent, and will report unanticipated 
problems involving risks to participants or others in accordance with Hospital X’s IRB 
Policies and Procedures and all federal requirements. Collection, recording, and reporting 
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of data was accurate and ensured the privacy, health, and welfare of participants during 
and after the study. As outlined in the implementation plan, patient confidentiality was 
maintained throughout the EBP project by removing patient identifiers, obtaining informed 
consent, and abiding by HIPAA regulations. 
All forms pertaining to the EBP project were distributed and collected by the DNP 
student to maintain consistency. Once completed by the consenting patients, the pre-
intervention and intervention questionnaires were immediately placed in a locked box in the 
oncology practice office, specifically, in the office of the project facilitator (Dr. X). Dr. X’s 
office was locked when not in use and only available to authorized personnel (e.g. nurse 
manager) during the working day. Participants were identified by numbers; no names were 
used. Identifiable patient information from the EMR was kept in a separate location at the 
DNP student’s home. Once the intervention period was completed, the DNP student 
brought the locked box home to analyze the data and input it into SPSS Statistics 25 and to 
analyze the data. A notebook was utilized to keep track of dates and times participants 
enrolled in the intervention and completed the questionnaires. This was kept in a locked 
filing cabinet in the office of Dr. X. The data will be kept locked in the office of Dr. X for 
three years following the EBP project, then shredded.  
Participants were advised that they could withdraw from the EBP project at any time 
without impacting their usual care. All data and records generated during the EBP project 
were kept confidential in accordance with Institutional Policies and HIPAA on subject 
privacy. The DNP student and project facilitator will not use the data and records for any 
purpose other than conducting the EBP project. No identifiable data will be used for future 
research without first obtaining IRB approval. Risks were expected to be minimal with this 
EBP project. There are anticipated to be no physical risks as a result of the EBP project 
were anticipated, but psychological risks from the intervention and project-related 
procedures could occur; including anxiety, depression, guilt, and loss of self-esteem. 
Strategies used to mitigate untoward psychological risks included developing a rapport 
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during the initial visit, using the same standard questionnaire at each telephone call, as well 
as providing reassurance, identifying the events as they occurred, and promptly reporting 
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The reduction of CINV remains a major clinical issue, as CINV is directly related to 
adherence to scheduled chemotherapy treatments and maintenance of patient quality of 
life (Coolbrandt et al., 2018). The purposes of this EBP project were to limit CINV and to 
determine the impact of interventions on reducing the number of health care visits related 
to CINV. This project addressed the following PICOT question: In adult patients with cancer 
who are undergoing chemotherapy, does a telephone intervention which includes the 
administration of a nausea questionnaire and APP-guided interventions at Days 2, 3 and 
10 post-chemotherapy decrease infusion center visits, ED visits, and hospitalizations 
related to CINV complications as compared to current practice (no telephone follow-up or 
nausea questionnaire) over a 16-week period of time? 
Participants 
 A number of statistical analyses were completed to determine if the participants in 
the EBP project were representative of the patient population within the oncology practice. 
The findings of those analyses are outlined in the paragraphs below.  
The average age of the participants in the EBP project was M = 66.6667 years (SD 
= 10.37416), with ages ranging from 43 to 81 (see Table 4.1). The mean age of the 
comparison group was M = 62.9167 years (SD= 12.65913). Using a paired-samples t-test, 
no significant difference in ages was found (t(23) = 1.041, p = .308), making the EBP 
project participants representative of the population.  
The literature showed that younger oncology patients are at higher risk for CINV 
(Underhill et al., 2015). But for participants in the lower half of the age bracket (ages 43-
67), the majority of participants (n = 10) reported symptoms equivalent with mild scores on 
the INVR questionnaire. These findings were equivalent to the CINV ratings of older 
participants. For participants in the upper half of the age bracket (ages 68-81), 10 
participants reported symptoms equivalent with mild scores on the INVR questionnaire, and 
two participants averaged moderate scores on the INVR questionnaire for this intervention. 
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Thus, there were no major differences in scores on the IVNR questionnaire between 
younger and older participants.  
 There were 15 males and 9 females who participated in the intervention: 63% 
males and 37% females. This is slightly more male dominant than the average patient 
population in the oncology practice, which was determined by sampling the population 
(comparison group), to be 57% male patients (n = 26) and 43% female patients (n = 19), 
but the intervention group was determined to be representative of the patient population 
within the practice ((1) = .22, p = .521).  
Participants in the EBP project consisted of 23 Caucasian participants (95.83%) 
and one African American participant (4.17%). In the comparison group, there were 38 
(84.44%) Caucasian patients, 5 African American patients (11.11%), 1 Asian patient 
(2.22%), and 1 patient (2.22%) who was of another race.  
There were six participants with lung cancer, five participants with lymphoma, four 
participants with head and neck cancers, four participants with breast cancer, two patients 
with colorectal cancer, one participant with cervical cancer, one participant with pancreatic 
cancer, and one participant with bladder cancer. These are reflective of the entire 
oncological patient population in the practice, in which the most common cancers were 
lung, head and neck, colon, and breast.  
 Twenty-three participants received high emetogenic chemotherapy, and one 
participant received moderate emetogenic chemotherapy. A variety of cancer stages were 
represented, partly due to the differences in staging of various cancers. Participants were 
most often diagnosed with a stage III or stage IV cancer. It can be extrapolated that this is 
reflective of the patient population, which has a 19% poverty rate, is of a low 
socioeconomic class, and is less likely to seek primary prevention health care and 
participate in screening that could provide a diagnosis at an earlier disease stage.  
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Six participants did not answer all three telephone calls, and therefore did not 
complete the INVR questionnaire three times. All of these participants answered two of the 
three telephone calls. They were all Caucasian and diagnosed with a variety of cancer 
types. For this subgroup, four participants had symptom ratings that resulted in mild scores 
in both of the telephone calls that they did answer. Two participants had symptom ratings 
that resulted in one mild score and one moderate score. None of the participants did not 
answer any of the telephone calls. The attrition data was not computable due to sample 
size, but there were no significant differences in age, gender, or race for participants that 
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Characteristics of the Participants  
________________________________________________________________________ 
  
                                                           n (%)         




    Male     15 (57)                         
 




    African American          1 (4) 
 




    Full-time       4 (17) 
 
    Not employed      6 (25) 
 
    Retired     14 (58) 
 
Level of Education  
 
    High school     14 (58) 
 
    Some college      3 (12.5) 
 
    College degree      4 (17) 
 




    Single       6 (25) 
 
    Married     12 (50) 
 
    Divorced        5 (21) 
 
    Widowed        1 (4) 
 
Note. N = 24. Participants were on average 66.3 years old (SD = 10.37416) and participant 
age did not differ by condition. 
 
Changes in Outcomes 
Statistical Testing and Significance  
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 Statistical analyses were conducted to evaluate the effectiveness of the intervention 
on CINV burden using INVR questionnaire scores within one group (N = 24). One-way 
repeated measures ANOVA compared mean scores for each of the three telephone call 
days. Paired samples t-tests were used to compare Day 2 scores to Day 3 scores, Day 3 
scores to Day 10 scores, and Day 2 scores to Day 10 scores. Statistical significance for all 
data was established as p < .05. One-way repeated measures ANOVA as well as 
independent samples t-tests compared INVR questionnaire scores for men and women. 
Additional comparison data were not run on level of education, race, employment status, 
and marital status.  
Findings 
Primary Outcome 
 The primary outcome of this EBP project was to decrease symptom burden related 
to CINV via INVR questionnaire and subsequent interventions. This was accomplished by 
comparing the number of infusion center visits, ED visits, and hospitalizations in the 
intervention group to the comparison group.  
The findings (see Table 4.2) supported that a telephone intervention and 
administration of a nausea questionnaire with APP-guided interventions decreased ED 
visits and hospitalizations related to CINV. Evaluation of the effectiveness of reducing each 
of these additional points of care are outlined in the following paragraphs.  
Statistical analyses were conducted to evaluate the effectiveness of the intervention 
for infusion center visits. For the comparison group, 1 of the 45 patients required at least 
one visit to the infusion center (2.22%). For the intervention group, 7 of the 24 participants 
(29.17%) required at least one visit to the infusion center at some point in the 16-week time 
period that the DNP student was completing the EBP project. Of these seven, five had 
infusion center visits during the 10-day period during which they were receiving calls and 
additional interventions. These five infusion center visits were all planned by the DNP 
student with the help of the staff at the oncology practice. The infusions consisted of IV 
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hydration, IV antiemetics, or both. When comparing the percentage of patients requiring 
infusion center visits, despite an increase in frequency among the intervention group, the 
increase was not statistically significant ((1) = 2.534, p = .111).  
Statistical testing was also completed to evaluate the effectiveness of the 
intervention for ED visits. Within the comparison group, although 23 patients went to the 
ED (with several patients seeking ED care more than once, for a total of 56 visits), ten of 
the 45 patients (22.22%) specifically required a visit to the ED for CINV-related illness. Only 
1 of the 24 intervention group participants (4.17%) required a visit to the ED during the 10-
day intervention period, but that visit was unrelated to CINV. Three additional participants 
did visit the ED at some point during the 16-week period of observation, and these were 
also not related to CINV. A chi-square test of independence was not able to be calculated 
comparing the number of ED visits between the comparison and intervention groups over 
16 weeks, because there were zero participants who required an ED visit for CINV in the 
intervention group.  
Finally, statistical testing also evaluated the effectiveness of the intervention for 
reducing hospitalizations for CINV-related illness. Within the comparison group, 6 of the 45 
patients required hospitalizations for CINV (13.33%), as compared to 1 of the 24 
intervention participants (4.17%). Two participants in the intervention group had 
hospitalizations from August 3, 2020 to January 2, 2021, but neither during the 10-day 
intervention. One hospitalization was partially related to CINV symptoms (4.17%), and the 
other was not related to CINV. Despite the 9-percentage point reduction in hospitalizations, 
which could be considered clinically significant, this finding was not improved to a 
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 The secondary outcome of this EBP project was to determine the impact of APP-
guided interventions on reducing symptom burden of CINV. This was done by comparing 
the mean scores on the INVR questionnaire at Day 2 to scores on the INVR questionnaire 
at Days 3 and 10. 
A repeated measures ANOVA was calculated comparing the INVR questionnaire 
scores for the group of participants at three different times: Day 2, Day 3 and Day 10 post-
chemotherapy. Twenty-one participants answered the telephone call on Day 2. Twenty-
three participants answered the telephone call on Day 3. Twenty-one participants also 
answered the telephone call on Day 10. Despite the intervention, a statistically significant 
increase in INVR questionnaire scores was noted (F(2,32) = 9.075, p < .001). 
Paired samples t-tests were performed to further analyze the data. Paired samples 
t-tests were conducted to compare participants who answered the telephone call on Day 2 
and Day 3; participants who answered the telephone call on Day 3 and Day 10; and 
participants who answered the telephone call on Day 2 and Day 10. As noted in the above 
paragraph, not all participants answered each call; therefore, the means used for these 
analyses do differ from the entire group analysis and they do differ within each of these 
three comparisons noted below. When comparing the mean INVR scores on Day 2 to Day 
3 (M = 3.100 vs. M = 5.800), the increase was not determined to be statistically significant 
(t(19) = -2.009, p = .059). When comparing mean INVR scores on Day 3 to Day 10, the 
increase was not determined to be statistically significant (t(19) = -1.618, p = .122)., but the 
increase in INVR scores did reach statistical significance t(19) = -5.014, p < .001) when 
Day 2 scores were compared to Day 10 scores (M = 2.700 vs. M = 10.400). 
A repeated measures ANOVA was also calculated comparing the INVR 
questionnaire scores for men and women. Despite the notation that women scored higher 
than men on each of the days, this difference did not reach statistical significance (F(2,30) 
= .874, p = .297). Additionally, independent samples t-tests were calculated. For Day 2, the 
mean score for men was 2.6047 (SD = 2.84400). The mean score for women was 3.8350 
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(SD = 3.86670). Scores between men and women on Day 2 were not statistically significant 
(t = -.810, p = .428). For Day 3, the mean score for men was 3.9336 (SD = 5.22110). The 
mean score for women was 8.3356 (SD = 7.32860). Despite women scoring higher on the 
INVR questionnaire on Days 2 and 3, the scores for Day 3 did not reach statistical 
significance (t = -1.686, p = .107). Finally, for Day 10, the mean score for men was 9.8350 
(SD = 9.73874). The mean score for women was 8.3356 (SD = 7.22553). Men scored 
higher on the INVR questionnaire on Day 10, but the scores did not reach statistical 
significance (t = .314, p = .702).  
Secondary Outcome Interventions. Scores on the INVR questionnaire were mostly mild 
(0-10); few participants reported moderate (11-20) or severe (21-30) symptoms (see Table 
4.2). Eight participants had symptom ratings that fell in the mild category on all three of 
their telephone calls. These participants were told to drink plenty of clear liquids daily, as 
well as to take their antiemetic as needed. Five participants had symptom ratings that 
resulted in two mild scores and one moderate score, one participant had symptom ratings 
that resulted in one mild score and two moderate scores, and one participant had symptom 
ratings equivalent to all moderate scores. They were provided the same education as 
participants who received a mild score but were also advised to take their antiemetic 
around the clock and drink at least 64 ounces of clear liquids daily; they were also notified 
that they would receive a telephone call from the oncology practice within 24 hours. There 
was one participant who had symptom scoring equivalent to one mild, one moderate, and 
one severe score. Because at least one score rating was severe, this participant was 
provided the same baseline education as those with mild and moderate scores but were 
also notified that they would be receiving a telephone call from the oncology practice within 
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Table 4.2 
Participant Scores and Interventions  
 Day 2       Day 3 Day 10               Add’l Interventions            Add’l Interventions 
 Score       Score Score               First Cycle          Subsequent Cycles 
 
1 0 (L)       0 (L)       8 (L)             None                                 None  
2 5 (L)       7 (L)     28 (S)            IC                                      None 
3 N/A       4 (L)       0 (L)               None                      None 
4 N/A      10 (L)      2 (L)               None                      None 
5 6 (L)        0 (L)      N/A               None                      None 
6 3 (L)        0 (L)       0 (L)               None                      None 
7 1 (L)        1 (L)       6 (L)               IC           IC 
8 0 (L)        0 (L)      N/A                       IC           None 
9 4 (L)        9 (L)      11 (M)                  IC x 3                      Hospitalization 
10 0 (L)        0 (L)       1 (L)    None           None 
11 0 (L)        N/A        15 (M)                  IC x 3, hospitalization       IC 
12 5 (L)        15 (M)     9 (L)    None           None 
13 0 (L)         0 (L)       0 (L)               IC           None 
14 6 (L)         0 (L)     19 (M)               None           None 
15 N/A         0 (L)       0 (L)               None           None 
16 8 (L)       12 (M)     N/A    None           None 
17 2 (L)         4 (L)       8 (L)      None           IC x 2 
18 0 (L)         4 (L)       2 (L)                   None           None 
19 6 (L)         0 (L)     15 (M)              None           None 
20 0 (L)         3 (L)       2 (L)     None           None 
21 10 (L)        18 (M)     18 (M)      IC           None 
22 1 (L)       17(M)       7 (L)      None           None 
23 0 (L)       10 (L)     18 (M)      None           None 
24 5 (L)       16 (M)    24 (S)        IC x 2           None 
________________________________________________________________________ 
*N/A = telephone call not answered  
IC = infusion center 
L = low 
M = moderate 
S = severe 
*Additional interventions only included those measured in the comparison group: infusion 
center visits, ED visits, and hospitalizations  
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There were some findings that warrant additional discussion. As noted in Table 4.2, 
three participants required infusion center visits in subsequent chemotherapy cycles. One 
of these participants also required an infusion center visit during their intervention period, 
and another participant also required a hospitalization. This patient opted for hospice 
services instead of completing all chemotherapy cycles. Most patients did not require the 
infusion center, ED, or hospital in subsequent chemotherapy cycles. However, many 
participants required additional interventions and/or additional office visits, both during the 
first chemotherapy cycle and subsequent chemotherapy cycles. On average, within this 
EBP project, participants 60 years of age and under had average INVR questionnaire 
scores slightly lower than participants 61 years of age and older. This is inconsistent with 
the literature reviewed for this EBP project, which revealed that those 60 years and 
younger were at higher risk for CINV (Underhill et al., 2015). In this EBP project, those who 
scored the highest on the INVR questionnaire (severe ratings, with scores greater than 20) 
were males in their 80s. Cancer type did not appear to be predictive of CINV. Nearly all of 
the participants received HEC chemotherapy, so there was no way to compare MEC 
versus HEC chemotherapy for INVR questionnaire scores.  
In summary, the intervention within this EBP project was effective for reducing ED 
visits and hospitalizations. Earlier intervention resulted in an increase in infusion center 
visits, which were more cost-effective therapies and provided participants a familiar 
environment. Unfortunately, the intervention was not effective for decreasing INVR 
questionnaire scores, but the scores did serve as an appropriate tool for initiating APP-









Explanation of Findings 
The purposes of this EBP project were to limit CINV and to determine the impact of 
APP-guided interventions on reducing the number of health care visits related to CINV, 
specifically infusion center visits, ED visits, and hospitalizations. At the conclusion of the 
EBP project, the DNP student had several findings about CINV which are outlined below.  
Primary Outcome 
 The primary outcome of this EBP project was to decrease the impact of symptom 
burden related to CINV by reducing infusion center visits, ED visits, and hospitalizations. 
Many of the APP-guided interventions were successful for doing so. When INVR 
questionnaire scores increased, the DNP student was able to initiate interventions, such as 
additional office visits, changes to therapies, and consults with physicians. The PICOT 
question was partially answered, with intervention group participants having fewer ED visits 
(0 in the intervention group vs. 22.22% of the comparison group) and hospital visits (2.22% 
in the intervention group vs. 29.17% of the comparison group). In comparison, the 
percentage of patients seen in the infusion center actually increased for the intervention 
group (29.17%) as opposed to the comparison group (2.22%). It is thought that the 
increased number of visits to the infusion center reflected that the sequelae of CINV were 
addressed in a timely, resource-efficient manner. These patients had contact with staff 
members who were more familiar with the participants and resulted in fewer ED visits and 
hospitalizations. It is anticipated that the decrease in ED visits and hospitalizations, 
although not statistically significant, were clinically significant. Furthermore, a previously 
completed power analysis set the number of participants required to achieve statistically 
significant results at 51 participants, white this project included only 24 participants. Thus, 
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the limited number of participants likely impacted the ability to achieve statistical 
significance despite the noted positive outcomes.  
 It is important to note the effectiveness of the APP-guided interventions for those 
who scored moderate scores on the INVR questionnaire. This appears to be the group in 
which the intervention was most helpful. Of importance is the finding that the DNP student 
was able to guide all participants and keep them out of the ED and hospital settings, the 
main goal of the EBP project. Extra contact with participants led to the use of additional 
antiemetic medications, extra appointments with the physicians, and infusion center visits. 
These were all critically important in reducing CINV complications and keeping participants 
out of the hospital setting.  
For those whose symptoms ratings resulted in severe scores on the INVR 
questionnaire, the intervention was moderately helpful. These patients were flagged by the 
physicians as being as “high risk” for CINV. These patients had more advanced cancers 
and co-morbidities. Therefore, these patients overall had the most interventions from the 
DNP student, as well as being seen in the ED and hospital.  
 Another finding that warrants explanation is the effect of the intervention on older 
adults, who often have co-morbid conditions, making them more likely to need an ED visit 
or hospitalization. The APP-guided interventions were especially effective for this group. 
Both of the participants were males over the age of 80, and these males reported 
symptoms equivalent with a “severe” rating on at least one call. The APP-guided 
intervention afforded the opportunity for their symptoms to be addressed in a timely, 
resource-efficient manner. Thus, fewer ED visits or hospitalizations were needed.  
 It is also of note that participants with head and neck cancers required more 
additional interventions compared to other types of cancer. While none of these 
participants were also receiving radiation, many of them reported mucositis, stomatitis, loss 
of appetite, and loss of taste. Additionally, almost all of the participants with head and neck 
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cancers reported gastrointestinal reflux symptoms. These are likely contributing factors in 
the need for more infusion center visits and other additional interventions.  
 
Secondary Outcome 
 The secondary outcome of this EBP project was to determine the impact of APP-
guided interventions, based on the INVR questionnaire scores, to reduce CINV. While the 
data and statistical analysis were mostly expected, some of the participant outcomes were 
not. For example, there were statistically significant increases in INVR questionnaire scores 
from Day 2 to Day 3 and Day 3 to Day 10, despite the intervention. Thus, one could 
summarize that the intervention was not beneficial in reducing CINV. But further discussion 
is warranted.  
 The supportive literature suggested patients experience the highest levels of 
nausea and vomiting 48 to 72 hours after receiving chemotherapy (Jackson et al., 2019). 
Therefore, the DNP student and project facilitator anticipated that CINV scores would 
increase from Day 2 to Day 3. Day 3 scores were anticipated by the project site facilitator 
and DNP student to be the highest. Neither the project facilitator nor the DNP student 
anticipated increases in scores from Day 3 to Day 10; therefore, patients had a 7-day 
period without telephone calls and APP-guided interventions to address the increase in 
CINV scores.  
 The majority of participants in this EBP project had mostly mild or “low” scores on 
the INVR questionnaire (13 of 24 participants had mild scores for all calls, while an 
additional 8 participants had only one moderate score among all calls), which was a 
somewhat unexpected finding, considering the significance of the impacts of CINV and the 
amount of research dedicated to it. Because most participants had mild scores on the INVR 
questionnaire, they received fewer education-based APP-provided interventions. Thus, it 
was impossible to determine if these patients would have benefited further from more 
intense APP-provided interventions (Rha et al., 2016 and Rico et al., 2017) 
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 Finally, the intervention did not seem to be more effective at controlling CINV 
symptoms for women than men. Women scored higher on the INVR questionnaire on Days 
2 and 3, and men scored higher on Day 10. Although women had higher mean scores on 
the questionnaire overall, they did not require more additional interventions than their male 
counterparts. Two women in the intervention group needed infusion center visits, while five 
men needed infusion center visits, with three men requiring at least two infusion center 
visits. This could be for a few reasons. Females, on average, spent more time on the 
telephone calls than their male counterparts. This resulted in more interventions like extra 
appointments with the oncologists and medication changes. Additionally, although a small 
difference, there were more single women in the intervention group compared to men. In a 
study by Winther et al. (2020), in their exploration of telephone-based interventions for 
healthcare, they found that participants liked someone to confide in regarding all health 
issues, access to professional and competent feedback, and a hotline for help and support. 
Women specifically were cited as valuing another voice to help them feel less burdensome 
to caregivers and protect their families from excessive worry (p. 3566). Males in the 
intervention group spent less time on the telephone calls and may have left out information 
that then resulted in more infusion center visits. This could also help explain why men had 
higher INVR questionnaire scores on Day 10.  
Strengths and Limitations of the DNP Project 
Strengths 
 The main strength of this EBP project was acceptability by staff (key stakeholders) 
and participants. There was an identified need for this type of intervention at the project 
site. Thus, the EBP project had strong support from the project facilitator, who was the 
most important key stakeholder in leading the practice change, and there was little to no 
resistance to change. The project facilitator also served as a resource when additional 
interventions (i.e., infusion center visits) were needed. Using the Iowa Model Revised, the 
project facilitator was involved in the feedback loops, and his feedback resulted in 
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adaptations for the project. For example, when it became difficult to obtain data for the 
comparison group, the project facilitator connected the DNP student to the oncology staff 
pharmacist, who gathered the data. Following the leadership provided by the project 
facilitator, the DNP student also had full support of the staff. These staff members were 
readily available during the oncology practice hours and answered questions in a timely 
manner. They also contacted patients in the appropriate time limits, and the DNP student 
was able to hand the intervention off to one staff nurse and one staff medical assistant 
easily and seamlessly at the end of the intervention period. Not surprisingly, based on the 
leadership of the physician, the intervention was also well-accepted and appreciated by 
participants; none of the participants that were approached declined to participate.  
 A final strength of the EBP project was the ease of using the widely used INVR 
questionnaire, which had previously established validity and reliability. The questionnaire 
did not require a significant amount of time for either participants or the DNP student to 
complete, and its use allowed the DNP student to guide participants through the initial 10 
days of chemotherapy treatment during a national pandemic and minimizing exposure to 
COVID-19 for this immunocompromised patient population.  
Limitations 
 A main barrier encountered was patient responsiveness and consequent attrition. 
Several patients did not answer all three telephone calls, and without additional follow-up, it 
is difficult to determine why the telephone call(s) were not answered or if additional 
interventions would have been warranted if the calls were answered. This limitation created 
some challenges to data analysis. Another barrier encountered was the difficulty enrolling 
participants. This was a limitation of the EBP project for a variety of reasons. First, the 
current healthcare climate and pandemic made scheduling appointments more difficult. 
Patients were also more hesitant to seek out providers and hospital settings. Oncology 
patients almost always require surgical procedures for biopsies and long-term IV access (at 
a minimum) for initial care, and this was unsettling for many due to a perceived increased 
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risk of exposure to COVID-19. Several patients also had difficulty with insurance before 
being able to start treatment, resulting in fewer participants initiating treatment even during 
an extended enrollment period.  
.  Another limitation was the timeframe designated for telephone call follow-up. Based 
on previous literature (Hesketh et al., 2017; Sun et al., 2020). CINV was measured at Days 
2, 3, and 10. Given the participants’ responses and lack of improvement in CINV scores 
(especially from Day 3 to Day 10), that schedule may not have been ideal.  
Implications for the Future 
There are several future implications in the areas of APP practice, theory, research, 
and education. This EBP project provided several themes and results that APPs should 
address as they relate to CINV and oncology care. There are also implications for the 
professional nurse in the areas of practice and education.  
Practice 
 Data analyzed within this EBP project revealed that a telephone intervention and 
administration of a CINV questionnaire decreased ED and hospital visits. This intervention 
was particularly helpful for groups identified as “high risk” for CINV (i.e., older adults) by 
providers. This translates into a need for oncology practices to be especially vigilant in 
follow-up with older adult patients, especially those 80 and older, as these adults are at 
higher risk for CINV complications. The additional vigilance may need to extend beyond a 
regular daily schedule; interventions for oncology patients are needed not only during office 
hours, but evenings and weekends as well. Future recommendations include a telephone 
line open to take calls twenty-four hours a day, seven days a week, as well as staff to 
respond to these patient needs. This can also include alternative follow-up strategies when 
telephone calls are not answered (e.g., an email follow-up or utilizing a family 
member/caregiver as a contact) when participants are unavailable or unable to answer 
calls. While this is best practice recommendation, it may be cost-prohibitive for most 
oncology practices. Still, the APP is best suited to provide additional interventions for CINV 
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management as an educator and leader; thus, to reduce practice costs the APP can also 
prepare the professional nurse to administer the INVR questionnaire via telephone calls 
and email.  
Because the telephone calls were helpful in keeping patients out of the ED and 
hospital during the first chemotherapy cycle, practices should consider using this 
intervention in subsequent chemotherapy cycles, provided the oncology practice can 
accommodate this service. As a leader, the APP could develop the policies and procedures 
for the staff to follow for all subsequent chemotherapy cycles. This initiative is especially 
important, as research has shown that cancer patients are most likely to report 
chemotherapy-related symptoms after the second chemotherapy cycle (Rha et al., 2016). 
Although a few symptom clusters have been identified as being stable throughout the 
chemotherapy (i.e., fatigue and loss of appetite/nausea), this further emphasizes the need 
for CINV intervention throughout the entirety of treatment (Rha et al., 2016).  
 This specific patient population was of low socioeconomic status and consisted of 
mostly retired Medicare recipients. Cost of treatments was a burden for this particular 
patient population; considering this limitation, financial concerns should be addressed as 
this project continues. The APP can work with insurance companies and other providers to 
provide this advocacy role for patients that need it. Considering the socioeconomic status, 
it is important to recognize that a telephone was necessary to participate in the 
intervention. This was not usually a problem for participants, although there were a few 
modifications made.  
In the future, it would be important for the APP to consider the culture of patient 
population. This EBP project was well-accepted by all participants, but that may not be the 
case in different settings.  
EBP Model 
The Iowa Model Revised has established success in leading practice change. 
Healthcare professionals find the model to be straightforward and linear (Iowa Model 
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Collaborative, 2017). While the staff within this EBP project did not have any significant 
challenges using the Iowa Model Revised, and subsequently implementing the practice 
change, critique of the model is that is can be too complex for novice healthcare 
professionals (Iowa Model Collaborative, 2017). Therefore, for this EBP project to be 
repeated or expanded, it should be noted that this EBP project works best with a small 
team led by skilled healthcare professionals. Ideally, an APP should form and lead the 
team, using a small group of dedicated staff (key stakeholders) to implement the change.  
Research 
 The evidence showed that patients starting chemotherapy for the first time should 
be educated about CINV, screened for symptoms of CINV, and provided with interventions 
to prevent or minimize CINV. There was also consistent evidence from the literature that 
demonstrated the effectiveness of using a telephone intervention is successful in aiding in 
minimizing CINV. Results from this EBP project were consistent with the research 
conducted by Basch et al. (2016) in that the intervention deceased ED visits. Yet, because 
the APP-guided interventions were not particularly effective at decreasing INVR 
questionnaire scores within this population, it would be appropriate to determine their 
effectiveness within other populations. It should be noted that this project did not have a 
comparison group that received the APP-guided interventions; thus, it is impossible to 
determine how high INVR questionnaire scores would have risen, if the earlier interventions 
were not implemented. Future research should focus on the development of effective, 
evidence-based interventions that can be standardized and used within oncology practice 
across the nation. Given the transition to telehealth during the pandemic, it would seem 
appropriate that future research include a focus on additional telehealth services to address 
CINV.  
 Additional areas of future research can focus on those individuals shown to be 
“outliers” in regard to the CINV scoring within this project. Ideally, effective strategies 
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should be developed to care for those most at risk for complications related to dehydration 
(e.g. those age 80 and older).  
 As the population for this EBP project was primarily white, middle-class American, it 
is also appropriate for additional research to focus on patients of color, who were 
underrepresented in this project and often not addressed within the research reviewed for 
this project. Including more diverse populations evaluated by the INVR questionnaire and 
managed APP-guided interventions would significantly add to the body of evidence 
regarding CINV management.  
 Because it was found that participants experienced nausea and vomiting later in the 
first chemotherapy cycle than anticipated, future research should focus on determining the 
most appropriate days for telephone calls to be made. Based on the findings of this EBP 
project, it was surmised that calling on Days 3, 8, and 10 may better reduce visits to the 
infusion center, ED, and hospital, but more research is needed.  
Future research could focus on the emotional support that additional follow-up care 
for CINV management provides. Consistent with the recommendations provided by Moretto 
et al. (2019), future research could also focus on self-management strategies for CINV 
management and compared to usual care (Mooney et al., 2016).  
In addition to previously identified recommendations for future evaluation, the 
standard for usual care may need to be further explored by researchers. Rha et al. (2016) 
stated that more than 75% of healthcare providers underestimated the incidence of delayed 
CINV and concluded that a change in CINV management, which would include a 5-HT3 
receptor antagonist, a NK1-receptor antagonist, and dexamethasone, would help reduce 
delayed CINV. Further research on these findings is warranted. Given the increase in INVR 
questionnaire scores on Day 10, it is important for future research to address delayed 
CINV. Janicki (2016), who reported that 58% of patients receiving MEC or HEC experience 
delayed CINV, with inconsistent prophylaxis being the main cause, used palonestron and 
netupitant (as compared to standard of treatment with a 5-HT3 receptor antagonist) to 
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combat delayed CINV. These diverse recommendations of CINV management draw 
attention to the need for the development more research-based universal management 
guidelines for CINV that could be implemented by the APP. It was beyond the scope of the 
DNP student to manipulate the current practice for CINV medication treatment, but this is a 
consideration for future research.  
Education 
 All oncology patients should be educated on CINV management. Best practice 
shows that reminders about CINV management through telephone follow-up calls helps 
reduce CINV. CINV education should be conducted with verbal instruction, written 
materials, and other visual resources such as videos and text message reminders or 
emails; in a leadership role, the APP can develop these educational tools. For nurse 
professionals and APPs, CINV management should be a part of training and continuing 
education, especially for those working in oncology settings. Hospitals can also incorporate 
CINV management education for those that work with an oncology patient population. 
Although a staff oncology nurse is optimally suited to administer questions surrounding 
CINV and direct patients to the next level of intervention or care, APPs are the best 
educated to provide CINV management because of their focus on holistic patient care as 
well as patient education. APPs, specifically NPs, provide physical, social, psychosocial, 
and existential patient care (van Dusseldorp et al., 2018). APPs, with their strong 
educational background, can serve as a link between oncologists and the rest of the 
oncological healthcare team.   
Conclusion 
 Nausea and vomiting are extremely common side effects of chemotherapy. The 
reduction of CINV remains a major clinical issue, as CINV is directly related to adherence 
to schedule chemotherapy treatments and maintenance of patient quality of life (Coolbrandt 
et al., 2018). The purposes of this EBP project were to limit CINV and to determine the 
impact of interventions on reducing the number of healthcare visits related to CINV: 
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specifically, infusion center visits, ED visits, and hospitalizations. This project addressed 
the following PICOT question: In adult patients with cancer who are undergoing 
chemotherapy, does a telephone intervention which includes the administration of a 
nausea questionnaire and APP-guided interventions at Days 2, 3 and 10 post-
chemotherapy decrease infusion center visits, emergency department (ED) visits, and 
hospitalizations related to CINV complications as compared to current practice (no 
telephone follow-up or nausea questionnaire) over a 16-week period of time? Ultimately, 
this EBP project was implemented to improve CINV symptom management and patient 
healthcare quality of life.  
Although the findings of this EBP project did not reveal a benefit of reducing CINV 
scores, the APP-guided intervention reduced the use of the ED and decreased the need for 
hospitalizations. The use of resources to address CINV was shifted to the infusion center, a 
more cost-effective approach. This EBP project inadvertently addressed the financial 
burdens on healthcare systems, especially during a global pandemic. During this time, it 
was difficult for patients to be seen in the ED in a timely manner, and it was also unlikely 
that caregivers could accompany patients to the ED or visit them while hospitalized. Thus, 
it was determined that the oncology practice and attached infusion center was a more 
appropriate place for this patient population, with providers who were familiar with the 
patients and access to services that were more readily available. Ultimately, although CINV 
scores did not improve significantly during the project, the decreased utilization of the ED 
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APPENDIX B 
INVR Questionnaire  
ID #: 
 
Date: Time:    
In the last 24 
hours, I threw up 
____ times. 
I did not 
throw up 
1-2 3-4 5-6 7 or more 
In the last 24 
hours, from 
retching or dry 
heaving, I have 
felt ____ distress.   
No Mild Moderate Great Severe 
In the last 24 
hours, from 
vomiting or 
throwing up, I 
have felt ____ 
distress. 
No Mild Moderate Great Severe 
In the last 24 
hours, I have felt 
nauseated or sick 
at my stomach 
____. 
Not at all 1 hour or 
less 
2-3 hours 4-6 hours 6 or more  
In the last 24 
hours, from 
nausea/sickness 
at my stomach, I 
have felt ____ 
distress. 
No Mild Moderate Great Severe 
In the last 24 
hours, each time I 
threw up,  I 
produced a ____ 
amount. 
I did not 
throw up 
Small (up 






(3 or more 
cups) 
In the last 24 
hours, I have felt 
nauseated or sick 
at my stomach 
____ times.  
None 1-2 3-4 5-6 7 or more 
In the past 24 
hours, I have had 
periods of 
retching or dry 
heaves without 
bringing anything 
up ____ times.  
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APPENDIX C 
Permission to use the Johns Hopkins Model and Tools 
 
 
Thank you for your submission. We are happy to give you permission to use the 
JHNEBP model and tools in adherence of our legal terms noted below: 
 
• You may not modify the model or the tools without written approval from Johns 
Hopkins.  
• All reference to source forms should include “©The Johns Hopkins Hospital/The 
Johns Hopkins University.” 
• The tools may not be used for commercial purposes without special permission.   












What is your age in years? _____________ 
 





What do you consider your race to be? (circle one or write in) 
Black or African American  
White or Caucasian 
Asian 
American Indian or Alaska Native 










Prefer not to answer 
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What is your level of education? (circle one) 
High school  
Some college 
College degree 
Beyond a college degree 
Other  
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The IRB determined that this study met the criteria for expedited review and approved the 
study from 7/15/2020 to 7/14/2021. Before 7/14/2021 or within 30 days of study closure, 
whichever is earlier, you are to submit a continuing review with required explanations. You 
can submit a continuing review by navigating to the active study and clicking Create 
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If continuing review approval is not granted on or before 7/14/2021, approval of this study 
expires after that date. This study will be due for continuing review on or before 7/14/2021 
inclusive. Failure to comply promptly with this continuing review process will result in an 
automatic suspension of the study.  
 
In conducting this study, you must follow the requirements listed in the Investigator Manual 
(HRP-200), which can be found by navigating to the IRB Library within the eIRB system. 
Approval by the IRB does not indicate institutional commitment of resources nor does it 
indicate privileges to perform new procedures.  
 
The Institutional Review Board is a duly constituted Institutional Review Board under 21 
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regulatory requirements.  
 
Please direct all inquiries to the IRB Office at 317-338-2194. 
